

Box 580

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**UTILITY PATENT APPLICATION
TRANSMITTAL LETTER
UNDER 37 C.F.R. 1.53(b)**

ATTORNEY DOCKET NO.:
52494/2202

Assistant Commissioner
for Patents
Washington D.C. 20231
Box Patent Application

Transmitted herewith for filing is the patent application of

Inventor(s): **DUFFY, Hao-Peng Xu; SHAN, Ji-dong; YUAN, Li-ming;
DUDMAN, Daniel and CALABRO, Anthony**

For : **IDENTIFICATION OF DIFFERENTIALLY METHYLATED
MULTIPLE DRUG RESISTANCE LOCI**

Enclosed are:

1. **32** sheets of specification, **10** sheets of claims, **1** sheet of abstract and **21** sheets of Sequence Listing.
2. **12** sheets of drawings.
3. Computer Readable Disk;
4. Statement that the Computer-Readable and Printed Sequence Listings are the Same (37 CFR §1.821(f));
5. Related Application:

The present application claims the benefit, under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 60/108,994 filed on November 18, 1998.

6. The filing fee has been calculated as shown below:

	NUMBER FILED	NUMBER EXTRA*	RATE (\$)	FEE (\$)
BASIC FEE				760.00
TOTAL CLAIMS	111 - 20 =	91	18.00	1,638.00

235561

Express Mail No. EL179103302US


INDEPENDENT CLAIMS	38 - 3 =	35	78.00	2,730.00
MULTIPLE DEPENDENT CLAIM PRESENT			260.00	260.00
*Number extra must be zero or larger			TOTAL	5,388.00
If applicant is a small entity under 37 C.F.R. §§ 1.9 and 1.27, then divide total fee by 2, and enter amount here.			SMALL ENTITY TOTAL	0.00

7. Please charge the required application filing fee of \$ **5,388.00** to the deposit account of **Kenyon & Kenyon**, deposit account number **11-0600**.
8. The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to the deposit account of **Kenyon & Kenyon**, deposit account number **11-0600**:
- A. Any additional filing fees required under 37 C.F.R. § 1.16;
 - B. Any additional patent application processing fees under 37 C.F.R. § 1.17;
 - C. Any additional patent issue fees under 37 C.F.R. § 1.18;
 - D. Any additional document supply fees under 37 C.F.R. § 1.19;
 - E. Any additional post-patent processing fees under 37 C.F.R. § 1.20; or
 - F. Any additional miscellaneous fees under 37 C.F.R. § 1.21.
9. A copy of this sheet is enclosed.

Dated:

Nov. 18, 1999

By:



Robin A. Chadwick, (Reg. No. 36,477)

KENYON & KENYON

One Broadway

New York, N.Y. 10004

(212) 425-7200 (telephone)

(212) 425-5288 (facsimile)

IDENTIFICATION OF DIFFERENTIALLY METHYLATED
MULTIPLE DRUG RESISTANCE LOCI

RELATED U.S. APPLICATIONS:

The present application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 60/108,994, filed November 18, 1998. The disclosures of U.S. Ser. No. 08/657,866, filed May 31, 1996, U.S. Ser. No. 09/163,951, filed September 30, 1998 and U.S. Ser. No. 09/345,881, filed June 30, 1999 are hereby incorporated by reference.

FIELD OF THE INVENTION:

The present invention provides nucleic acids isolated by Methyl- (or Mutant-) Differential Display (MDD) methods and methods for detecting mutations and/or the methylation patterns in multiple drug resistance loci. Genes are frequently not methylated in the cells where they are expressed but are methylated in cell types where they are not expressed. Moreover, tumor cell DNA is frequently methylated to a different extent and in different regions than is the DNA of normal cells. According to the present invention, the methylation pattern in a multiple drug resistance locus can, surprisingly, be altered and can give rise to altered expression patterns of that multiple drug resistance locus. Nucleic acids corresponding to the identified loci are useful as probes for detecting mutations and methylation patterns of the newly identified genomic loci, and of homologous nucleic acids. Nucleic acids of the present invention are also useful for detecting expression of mRNA from herein identified genes, for measuring expression of those and homologous genes sequences, and for determining suitability of therapeutic treatment. The disclosed nucleic acids and their homologs are useful for inhibition of multiple drug resistance. Cells are disclosed which are useful for identification or modulators of multidrug resistance.

BACKGROUND OF THE INVENTION:

DNA is often methylated in normal mammalian cells. Patterns of DNA methylation have been found to correlate with patterns of gene expression. For example, differential methylation is found where maternal and paternal alleles of a gene in a zygote are differentially expressed. See Melissa Little et al., *Methylation and p16: Suppressing the Suppressor*, 1 NATURE MEDICINE 633 (1995). While methylation is known to occur at CpG sequences, only recent studies indicate that CpNpG sequences may be methylated. Susan J. Clark et al., *CpNpG*

EL 179 10330245

Methylation in Mammalian Cells, 10 NATURE GENETICS 20, 20 (1995). Methylation at CpG sites has been much more widely studied and is better understood.

Methylation of CpG sequences occurs by enzymatic recognition followed by placement of a methyl (CH₃) group on the fifth carbon atom of a cytosine base. The enzyme that mediates methylation of CpG dinucleotides, 5-cytosine methyltransferase, is essential for embryonic development -- without it embryos die soon after gastrulation. It is not yet clear whether this enzyme methylates CpNpG sites. Peter W. Laird et al., *DNA Methylation and Cancer*, 3 HUMAN MOLECULAR GENETICS 1487, 1488 (1994).

When a gene has many methylated cytosines it is less likely to be expressed. K. Willson, 7 TRENDS GENET. 107-109 (1991). Hence, if a maternally-inherited gene is more highly methylated than the paternally-inherited gene, the paternally-inherited gene will generally give rise to more gene product. Similarly, when a gene is expressed in a tissue-specific manner, that gene will often be unmethylated in the tissues where it is active, but will be highly methylated in the tissues where it is inactive. Incorrect methylation is thought to be the cause of some diseases, including Beckwith-Wiedemann syndrome and Prader-Willi syndrome. I. Henry et al., 351 NATURE 665, 667 (1991); R.D. Nicholls et al., 342 NATURE 281, 281-85 (1989).

The methylation patterns of DNA from tumor cells are generally different than those of normal cells. Laird et al., *supra*. Tumor cell DNA is generally undermethylated relative to normal cell DNA, but selected regions of the tumor cell genome may be more highly methylated than the same regions of a normal cell genome. Hence, detection of altered methylation patterns in the DNA of a tissue sample is an indication that the tissue is cancerous. For example, the gene for Insulin-Like Growth Factor 2 (IGF2) is hypomethylated in a number of cancerous tissues, such as Wilm's Tumors, rhabdomyosarcoma, lung cancer and hepatoblastomas. Rainner et al. 362 NATURE 747-49 (1993); Ogawa, et al., 362 NATURE 749-51 (1993); S. Zhan et al., 94 J. CLIN. INVEST. 445-48 (1994); P.V. Pedone et al., 3 HUM. MOL. GENET. 1117-21 (1994); H. Suzuki et al., 7 NATURE GENET 432-38 (1994); S. Rainier et al., 55 CANCER RES. 1836-38 (1995).

The present invention is directed to nucleic acids which are differentially methylated in cells exhibiting multiple drug resistance relative to drug sensitive cells. Such nucleic acids, including nucleic acids specifically disclosed herein, are isolated by virtue of differential methylation at CpG dinucleotide or CpNpG trinucleotide sequences. Surprisingly, nucleic acids disclosed herein are homologous, but not identical, to members of a known gene family,

particularly the RAB6 gene. We adhere to the nomenclature whereby human genes are designated with uppercase letters (e.g., WTH3, RAB6C, RAB6), and designate encoded proteins and peptides with lowercase letters (e.g., wth3, rab6c, rab6).

Multiple drug resistances (MDR) to a broad spectrum of chemotherapeutic agents is a major obstacle in the clinical treatment of human cancer. The most extensively studied proteins, *mdr1* and *mrp*, are structurally similar to, and are members of, the ATP-binding cassette (ABC) transporter family. Previous studies provide no cytogenetic or molecular proof of gene amplifications which might explain an elevated expression of MDR1 or MRP genes. The present invention provides nucleic acids which are homologous to the RAB6 locus. Surprisingly, the present nucleic acids were isolated because they are hypermethylated in a drug resistance cell line. Moreover, rather than being over-expressed, the present nucleic acids appear to be underexpressed in multiple drug resistance cells.

SUMMARY OF THE INVENTION:

The present invention provides an isolated nucleic acid encoding a human *wth3* protein or an immunogenic fragment thereof. The nucleic acid can encode an amino acid sequence comprising SEQ ID NO:12 from about amino acid residue number 1 to about amino acid residue number 175. The nucleic acid can be SEQ ID NO:7 or SEQ ID NO:11. Alternatively, the nucleic acid can encode immunogenic fragments of *wth3* which comprise amino acids of SEQ ID NO:19, or SEQ ID NO:20, or SEQ ID NO:21, or SEQ ID NO:22, or SEQ ID NO:23 or SEQ ID NO:24.

The present invention also provides an isolated nucleic acid encoding a human *rab6c* protein or an immunogenic fragment thereof. The nucleic acid can encode an amino acid sequence comprising SEQ ID NO:27 from about amino acid residue number 1 to about amino acid residue number 208. The nucleic acid can be SEQ ID NO:25 or SEQ ID NO:26.

The present invention is also directed to a recombinant DNA and an expression vector which includes any one of the present nucleic acids operably linked to regulatory control nucleic acid which effects expression of the nucleic acid in a host cell.

The present invention is further directed to a host cell which contains such a recombinant DNA or such an expression vector.

The present invention also contemplates a process for producing a recombinant *wth3* protein or immunogenic fragment thereof, or a recombinant *rab6c* protein or immunogenic

fragment thereof. The process involves: a) culturing a host cell which contains an expression vector having one of the present nucleic acids in a culture medium under conditions suitable for expression of one of said recombinant proteins in the host cell, and b) isolating the recombinant protein from the host cell or the culture medium.

The present invention further contemplates a substantially purified protein or polypeptide which comprises amino acids of SEQ ID NO:12 or SEQ ID NO:19 or SEQ ID NO:20 or SEQ ID NO:21 or SEQ ID NO:22 or SEQ ID NO:23 or SEQ ID NO:24. Alternatively, the substantially purified protein can include the amino acid sequence depicted in SEQ ID NO: 27 from about amino acid residue number 1 to about amino acid residue number 208.

The present invention is also directed to an isolated nucleic acid which includes a sequence of at least about 12 nucleotides, preferably at least about 15 nucleotides of SEQ ID NO:10 which is capable of hybridizing to a nucleic acid segment of a WTH3 gene under hybridization conditions wherein the nucleic acid fails to hybridize to a nucleic acid segment of a RAB6 gene. In one embodiment the hybridization conditions are stringent.

The present invention also provides an isolated nucleic acid which includes SEQ ID NO:10 from about nucleotide number 1 to about nucleotide number 838. In another embodiment such an isolated nucleic acid can have at least 20 adjacent nucleotides of SEQ ID NO:10; such a nucleic acid may have up to at least 100 adjacent nucleotides of SEQ ID NO:10.

The present invention further provides an antibody which binds to wth3 protein, wherein the affinity of such an antibody for the wth3 protein is greater than the affinity of the antibody for a rab6 protein. The wth3 protein can comprise the amino acid sequence of SEQ ID NO:12 from about amino acid residue number 1 to about amino acid residue number 254. In a preferred embodiment the antibody binds to wth3 and not to rab6. Methods of producing a hybridoma which secretes such an antibody are also provided. Such a method includes a) immunizing an animal with wth3 or a polypeptide fragment thereof; b) obtaining lymphoid cells from the immunized animal; c) fusing the lymphoid cells and an immortalizing cell to produce hybrid cells; and d) selecting hybrid cells which produce antibody that: i) specifically binds to wth3, and ii) does not bind to rab6.

The present invention further provides a method for identifying wth3 in a test sample, which includes a) contacting the test sample with an anti-wth3 antibody or fragment thereof that specifically binds to wth3 protein, such that wth3 protein binds to the anti-wth3 antibody and forms a complex therewith; b) contacting the complex with a reporter molecule which includes a

signal generating compound capable of binding to the anti-wth3 antibody or fragment thereof; and c) detecting the signal generating compound, to thereby detect the wth3 protein. This method may also include an additional step where a control sample having substantially no wth3 protein is contacted with the anti-wth3 antibody or fragment thereof.

5 The present invention also provides a method for identifying wth3 protein in a test sample, which includes: a) contacting the test sample with a first anti-wth3 antibody that specifically binds to wth3 protein, such that wth3 protein binds to the first antibody and forms a complex therewith; b) contacting the complex formed in step (a) with a second antibody that specifically binds to wth3 protein so as to form a second complex which includes the first
10 antibody, the wth3 protein, and the second antibody; c) contacting the second complex formed in step (b) with a reporter molecule that includes a signal generating compound wherein the reporter molecule is capable of binding to said first or second anti-wth3 antibody; and d) detecting the signal generating compound, thus detecting the wth3 protein. In a particular embodiment, either of the first or second anti-wth3 antibody is capable of being attached to a support. According to the present invention, either the first or the second anti-wth3 antibody has a greater affinity for wth3 protein than for rab6 protein. For example, the anti-wth3 antibody can have 1000-fold greater affinity for wth3 protein than for rab6 protein. In the preferred embodiment, the anti-wth3 antibody binds to wth3 protein and does not bind to rab6 protein. This method can also include a step for observing whether the first and the second antibody bind
20 to a control sample having substantially no wth3 protein.

 The present invention further involves a method for detecting whether a CG dinucleotide or a CNG trinucleotide is hypomethylated or hypermethylated in a genomic DNA homologous to WTH3 which is present in a test sample of cells. This method includes a) cleaving genomic DNA isolated from the test sample of cells with a master restriction enzyme to generate a
25 cleaved test-cell DNA; b) hybridizing a probe to the cleaved test-cell DNA to form a hybridization complex; and c) determining the size of the hybridization complex; wherein the master restriction enzyme cleaves a nonmethylated CG or CNG DNA sequence but does not cleave a methylated CG or CNG DNA sequence, and wherein the probe is a nucleic acid which hybridizes to a WTH3 nucleic acid in the region of the CG or CNG sequence. The method may
30 also include cleaving genomic DNA isolated from a control sample of cells, hybridizing a probe to the cleaved control-cell DNA to form a control-hybridization complex and determining whether the size of the control-hybridization complex is the same as the size of the test-

hybridization complex. According to the present invention, the potentially methylated CG or CNG sequence is within 10 kb of the transcribed WTH3 sequence. The master restriction enzyme can be *Hpa* II.

By properly choosing the hybridization probe of step (b), the same method is useful for determining whether a CG dinucleotide or a CNG trinucleotide is hypomethylated or hypermethylated in the region of DNA which comprises RAB6.

The present invention also includes a method of identifying human WTH3 mRNA in a test sample which includes contacting a test sample with a nucleic acid probe that has a nucleotide sequence which is complementary to a portion of human WTH3 mRNA, and determining whether the probe hybridizes to an mRNA in the test sample. In another embodiment, this method involves an additional step of measuring the amount of WTH3 mRNA by measuring the amount of probe hybridized to the WTH3 mRNA. Measurements of WTH3 mRNA are made to determine whether the amount of WTH3 in a test sample is elevated or diminished. Amounts of WTH3 mRNA in different cells can be compared. For example, it is disclosed that the amount of WTH3 mRNA in multidrug resistant MCF7/AdrR cells is reduced compared to drug sensitive MCF7 cells. Alternatively, the amount of WTH3 mRNA in a particular cell is compared to the amount of one or more RNA species which are constitutively expressed. Two examples of such RNAs are those which encode β -actin and glyceraldehyde-3-phosphate dehydrogenase (GPDH).

In a preferred embodiment, the hybridization conditions prevent hybridization of the probe to an mRNA encoding a human rab6 protein but permit hybridization to an mRNA encoding a human wth3 protein. Preferred probes for detecting and measuring WTH3 mRNA contain nucleotide sequences which are specific to WTH3. However, probes which bind to any part of WTH3 may be useful. For example, a probe which hybridizes to both RAB6 and WTH3 can be used to measure RAB6 mRNA and WTH3 mRNA simultaneously. When comparing samples such as RNA from MCF7 and MCF7/AdrR cells, where both WTH3 and RAB6 mRNAs are differentially expressed in a similar fashion, it may not be necessary to differentiate between the two mRNA species. Of course, two such mRNA species may nevertheless be differentiated if necessary by some other characteristic. For example, it is possible to individually measure two homologous RNA species using a northern blot to separate them by size.

5 The present invention further provides a method for identifying human WTH3 mRNA in
a test sample which includes nucleic acid amplification of an mRNA homologous to WTH3.
This method may involve polymerase chain reaction (PCR) of an mRNA present the test sample
using a first and a second PCR primer. For example, the method may involve annealing a first
10 PCR primer to a test sample RNA, reverse transcribing an RNA homologous to WTH3 to
provide a cDNA:RNA hybrid, melting the RNA:DNA hybrid to provide a single-stranded
cDNA, annealing a second PCR primer onto the cDNA, primer-extending said second PCR
primer to form a double stranded DNA, amplifying the double-stranded DNA using the first
PCR primer and the second PCR primer to form an amplified double-stranded DNA, and
15 detecting the amplified double-stranded DNA. In this example, the first PCR primer is
complementary to a 3' portion of an WTH3 mRNA and may have SEQ ID NO:9, whereas the
second PCR primer is complementary to the 3' end of the cDNA and may have SEQ ID NO:8 or
SEQ ID NO:28.

20 The methods and nucleic acids of the present invention which are useful for determining
expression of WTH3 are also useful for measuring expression of WTH3 and WTH3 homologs.
For example, the present invention provides methods and nucleotides useful for measuring
expression of RAB6C and RAB6. Using nucleotides of the present invention, it is shown that
other mRNAs in addition to WTH3 are differentially expressed. The discovery of differential
expression of WTH3 in normal and multiple drug resistant cells is extended to homologs of
WTH3, including RAB6C and RAB6. Particular probes designed to measure expression of
RAB6 also reveal expression of other homologous mRNAs of differing sizes. Similar to WTH3,
it is observed that RAB6 and RAB6 homologs are differentially expressed in MCF7 and
MCF7/AdrR drug resistant cells. The present invention contemplates kits and methods for the
measurement of WTH3, RAB6 and their homologs, either individually or in combination.

25 By determining expression of WTH3, or RAB6C, or RAB6, or a homolog in a test
sample from a cancer, the suitability of certain drugs for treatment of the cancer can be
determined. For example, identification of a deficiency in expression in any of the
aforementioned genes, would indicate discontinuation of and substitution for a therapeutic that is
substantially ineffective for treatment of cells which have acquired multidrug resistance.

30 Nucleic acids of the present invention, when expressed in cells which otherwise exhibit
MDR, are useful for inhibition of the drug resistant phenotype. The nucleic acids are shown to
be useful for increasing drug sensitivity of MDR cells to doxorubicin. The present invention

contemplates the use of nucleic acids homologous to RAB6 for the treatment of MDR cells and tumors.

Moreover, cells which overproduce *wth3* or *rab6c* or *rab6* or a homolog thereof are useful for identifying modulators or multidrug resistance.

BRIEF DESCRIPTIONS OF THE DRAWINGS:

Fig. 1 provides a nucleotide sequence comparison of WTH3 (top) and RAB6 (bottom, GenBank Accession No. M28212) DNA sequences. The ATG start codons and the TAA termination codon of RAB6 are underlined. Nucleotide numbers correspond to GenBank Accession No. M28212 (RAB6) and SEQ ID NO:10 (WTH3).

Fig. 2 provides an amino acid sequence comparison of *wth3* (top) and *rab6* (bottom). Conservative substitutions are represented by "+".

Fig. 3 provides a comparison of RAB6C (top) and RAB6 (bottom) DNA sequences. The ATG start and TAA termination codons are underlined.

Fig. 4 provides an amino acid sequence comparison of *rab6c* (top) and *rab6* (bottom). Conservative substitutions are represented by "+".

Fig. 5 depicts a Northern blot of mRNA from a non-drug resistant cell line, MCF7, and a drug resistant cell line, MCF7/AdrR, hybridized with a probe containing WTH3 sequences. The probe was prepared by amplification of a 573 bp WTH3 fragment which had been cloned into pUC118 (see Example 1). For quantitative comparison, the same mRNA was hybridized to a control probe which comprised a nucleotide sequence encoding a portion of β -actin, which is expressed in all tissues. As indicated by the density of the band, WTH3 transcripts are present at significantly higher levels in mRNA isolated from the non-drug resistant MCF7 cells (lane W) than in mRNA isolated from the drug resistant MCF/AdrR cells (lane A).

Fig. 6 depicts a northern blot of mRNA from non-drug resistant MCF7 cells (lane W) and drug resistant MCF7/AdrR cells (lane A) hybridized with a probe containing 208 bp of RAB6 sequence. For quantitative comparison, the same mRNA was hybridized with a control probe which comprised a nucleotide sequence encoding a portion of glyceraldehyde-3-phosphate dehydrogenase (GPDH). The *RAB6* probe identified several bands, all of which appear with greater intensity in lane "W" relative to lane "A". The bands correspond to transcripts sizes ranging from 1.5 kb to over 4 kb.

Fig. 7 depicts the results of a quantitative RT-PCR experiment for detecting amounts of RAB6 and WTH3/RAB6C transcripts in MCF7/AdrR cells (lanes labeled "R") and MCF7 cells (lanes labeled "W") genes. cDNA was synthesized from mRNA and amplified. β -actin served as a control as it is normally is expressed in all tissues. Amplification products for positive controls are shown in lanes labeled β -actin (495 bp), Rab6 (244 bp) and Rab6c (244 bp). For the R-W lane pair labeled Rab6, β -actin and RAB6 amplification products were generated in a single reaction using β -actin and RAB6 specific primers. The amount of RAB6 product is significantly reduced in MCF7/AdrR cells relative to MCF7 cells. For the R-W lane pair labeled Rab6c, β -actin and WTH3/RAB6C amplification products were generated in a single reaction using β -actin and WTH3/RAB6C specific primers. The amount of WTH3/RAB6c product is significantly reduced in MCF7/AdrR cells relative to MCF7 cells.

Fig. 8 depicts the results of a flow cytometry experiment measuring retention of doxorubicin in MCF7/AdrR cells transfected with pcDNA/RAB6C (panel A), pcDNA/RAB6 (panel B), or pcDNA1.1/Amp (control, panelC), compared with non-transfected cells (panel D). In each graph, the solid thin line represents untreated cells, the solid bold line represents cells loaded with doxorubicin for 2 hours. The dotted thin and bold lines represent doxorubicin loaded cells after 3 and 5 hours of chase.

Fig. 9 depicts fluorescence microscopy of MCF7/AdrR cells transfected with pcDNA/RAB6 (A, B, G, H), pcDNA/RAB6C (C, D, I, J) and pcDNA1.1/Amp (E, F, K, M) and loaded for 2 hours with doxorubicin. Panels A, C and E are bright field views at the end of the loading period. Panels B, D, and F show the corresponding fluorescence. Panels G, I, and K are bright field views following a 6 hour chase without doxorubicin. Panels H, J, and M show the corresponding fluorescence. Magnification 150X.

Fig. 10 depicts expression by quantitative PCR of WTH3 mRNA in patients diagnosed with chronic lymphocytic leukemia (CLL; panel a), acute myelogenous leukemia (ALL; panel b), and acute lymphocytic leukemia (ALL; panel c). In each patient sample lane (numbered) the 343 bp product generated with WNT3 specific primers is compared with the 495 bp product generated simultaneously with β -actin specific primers. Lanes marked "MW" have a molecular weight standard. Lanes marked "NR" are from a normal control. Lanes marked "WTH3" show quantitative PCR results using a WTH3 standard. Lanes marked " β -actin" show quantitative PCR results using a β -actin standard. Lane "N" is a negative control.

DETAILED DESCRIPTION OF THE INVENTION:

The present invention is directed to genomic loci which are differentially methylated in multiple drug resistant cells compared to non-multiple drug resistant cells. One of the present genomic loci is WTH3, which is homologous to a known locus, the RAB6 locus. The WTH3 genomic locus has a nucleotide sequence which comprises SEQ ID NO:7, and encodes an open reading frame. The complete coding sequence of the wth3 protein is represented by SEQ ID NO:11. The encoded 254 amino acid wth3 protein is represented by SEQ ID NO:12.

The present WTH3 genomic locus was isolated by Methyl- Differential Display ("MDD") methods as disclosed in U.S. Ser. No. 08/657,866, filed May 31, 1996, which is hereby incorporated by reference. MDD is used for detecting and isolating DNA fragments that are normally methylated in one cell type, but which, for some reason, are hypo- or hyper-methylated in another cell type. Such DNA fragments may normally be methylated for a number of reasons. For example, such DNA fragments may be normally methylated because they contain, or are associated with, genes that are rarely expressed, genes that are expressed only during early development, genes that are expressed in only certain cell-types, and the like. According to the present invention, the WTH3 locus is hypermethylated in drug resistant cells relative to non-drug resistant cells. Moreover, multiply drug resistant cells express less WTH3 mRNA than non-drug resistant cells.

Hence, the present nucleic acids can be used to detect aberrant expression in cells suspected of being multiply drug resistant. Moreover, the present nucleic acids can be used for detecting hypomethylation, hypermethylation or a mutation in homologous DNA fragments. Similarly, the present genomic nucleic acids can be used to detect expression of homologous mRNAs and to isolate homologous cDNAs.

As used herein, hypomethylation means that at least one cytosine in a CG or CNG di- or tri-nucleotide site in genomic DNA of a given cell-type does not contain CH₃ at the fifth position of the cytosine base. Similarly, as used herein, hypermethylation means that at least one cytosine in a CG or CNG di- or tri-nucleotide site in genomic DNA of a given cell-type does contain CH₃ at the fifth position of the cytosine base.

Cell types which may have hypo- or hyper-methylated CGs or CNGs include any cell type which may be expressing a tissue-specific, cell-type specific or non-housekeeping gene. This includes both normal cells that express tissue-specific or cell-type specific genetic functions, as well as tumorous, cancerous, and similar cell types. Cancerous cell types and

conditions which can be analyzed or diagnosed by the present methods include Wilm's cancer, breast cancer, ovarian cancer, colon cancer, kidney cell cancer, liver cell cancer, lung cancer, leukemia, rhabdomyosarcoma, sarcoma, and hepatoblastoma. Test cell types can therefore include cells that express tissue or cell-specific functions, cancer cells, tumor cells and the like.

5 A control cell type may be simultaneously tested. Such a control cell type is preferably an undiseased cell of the same cell type as the test cell. For example, if breast cancer cells are selected as the test cell type, the normal cell type would be breast cells that are not diseased or cancerous. Preferably, test and normal cell types are isolated from the same person. Test sample and control sample nucleic acids can be obtained from any mammalian body fluid,
10 secretion, cell-type, or tissue, as well as any cultured cell or tissue.

According to the present invention, a mutation, hypomethylation and hypermethylation at a specific site in genomic DNA can be detected by observing whether the size or intensity of a DNA fragment cut with a methylation sensitive restriction enzyme is the same in control and test samples. This can be done by cutting genomic DNA isolated from control and test tissue
15 samples with the methylation-sensitive ("master") restriction enzyme, hybridizing a probe to the control and test DNAs and observing whether the two hybridization complexes are the same or different in size or intensity.

After isolation, the test sample and control sample DNA are separately cut with restriction enzymes. For detecting and isolating hypomethylated or hypermethylated DNA sites, a methylation-sensitive restriction enzyme should be used. The selection of a methylation-sensitive restriction enzyme for the practice of the present invention is within the skill of an artisan in the field. Cleavage methods and information for selecting restriction enzymes for cutting DNA at specific sites are known to the skilled artisan. For example, many suppliers of restriction enzymes provide information on conditions and types of DNA sequences cut by
20 specific restriction enzymes, including New England BioLabs, ProMega Biochem, Boehringer-Mannheim and the like. Sambrook et al. provide a general description of methods for using restriction enzymes and other enzymes. See Sambrook et al., 1989 Molecular Cloning: A Laboratory Manual, Vol. 1-3 (Cold Spring Harbor Press, Cold Spring Harbor, NY). In one embodiment, the *Msp* I restriction enzyme is used which recognizes and cleaves DNA at
25 nonmethylated CCGG but will not cleave the CCGG sequence when the outer cytosine is methylated. Other methylation sensitive enzymes contemplated by the present invention include *Hpa* II *Bsi* I, *Hin*2 I and the like.

Nucleic acids homologous to the present WTH3 nucleic acid can be detected by any procedure available to one of skill in the art. For example, hybridization techniques are frequently used for detecting nucleic acids and the present invention contemplates all available hybridization techniques, including Southern, Northern and in situ hybridization techniques.

In particular, the present invention provides a method for detecting whether a CG or CNG sequence is hypomethylated or hypermethylated in a genomic DNA homologous to WTH3 which is present in a test sample of cells. This method includes:

- a) isolating genomic DNA from a control sample of cells and a test sample of cells to generate a control-cell DNA and a test-cell DNA;
- b) cleaving the control-cell DNA and the test-cell DNA with a methylation-sensitive restriction enzyme to generate cleaved control-cell DNA and cleaved test-cell DNA;
- c) preparing a probe capable of hybridizing to a WTH3 nucleic acid or a homologous nucleic acid known to demonstrate cell-type specific methylation patterns;
- d) hybridizing the probe to the cleaved control-cell DNA and the cleaved test-cell DNA to form a control-hybridization complex and a test-hybridization complex; and
- e) observing whether the size of the control-hybridization complex is the same as the size of the test-hybridization complex.

In one embodiment, the probe may include a WTH3 nucleic acid, which may be selected, for example, from SEQ ID NO:7, SEQ ID NO:10, or SEQ ID NO:11. In another embodiment, the probe can be a RAB6C nucleic acid, for example, SEQ ID NO:24 or SEQ ID NO:25.

Similarly, the present invention provides a method of detecting whether a DNA site is mutated in a genomic DNA homologous to a WTH3 nucleic acid which is present in a test sample of cells. This method includes:

- a) isolating genomic DNA from a control sample of cells and a test sample of cells to generate a control-cell DNA and a test-cell DNA;
- b) cleaving the control-cell DNA and the test-cell DNA with a detector restriction enzyme to generate cleaved control-cell DNA and cleaved test-cell DNA;
- c) preparing a probe from a discrete DNA isolated by the methods of the present invention;
- d) hybridizing the probe to the cleaved control-cell DNA and the cleaved test-cell DNA to form a control-hybridization complex and a test-hybridization complex; and

e) observing whether the size of the control-hybridization complex is the same as the size of the test-hybridization complex;

wherein the detector restriction enzyme does not cleave a mutated DNA site but does cleave a corresponding nonmutated DNA site.

5 The skilled artisan can vary the hybridization conditions used for detecting homologous nucleic acids to achieve optimal hybridization. Conditions for achieving optimal hybridization are known to the skilled artisan and generally include probe length, temperature and salt concentrations permitting selective hybridization between two highly homologous DNA fragments, e.g. stringent hybridization conditions. Stringent conditions permit little or no
10 detectable hybridization between mismatched driver or tester fragments, that is between fragments that have dissimilar sequences, particularly at the ends. Hybridization techniques are described, for example, in Sambrook et al., 1989 Molecular Cloning: A Laboratory Manual, Vols. 1-3 (Cold Spring Harbor Press, Cold Spring Harbor, NY).

15 It is well known in the art to adjust hybridization and wash solution salt conditions and temperatures such that stringent hybridization conditions are obtained. Preferred stringent conditions are those that allow a probe to hybridize to sequences which are more than 90% complementary to the probe and not to those which are less than 70% complementary. Stringency depends on such parameters as the size and nucleotide content of the probe being utilized. See Sambrook et al. and other sources for general descriptions and examples.

20 Hybridization techniques for detecting specific genomic DNA fragments are known in the art and include solid-phase-based hybridization and solution hybridization which use any of the known reporter molecules. Detailed methodology for gel electrophoretic and nucleic acid hybridization techniques can be found in Sambrook et al.

25 Using the nucleotide sequences provided herein, probes can be constructed which are useful as reagents for detecting the susceptibility of particular DNA sequences in a test sample to cleavage by restriction endonucleases. Such susceptibility to cleavage is affected by factors which include methylation of particular bases and the substitution of bases through mutation. For example, from the sequences provided, it is possible to generate nucleic acid probes to determine the sizes and relative amounts of particular DNA species which result when DNA
30 recovered from a test sample is digested with selected sequence specific endonucleases. Preferred nucleic acid probes for detecting hypomethylation, hypermethylation and mutation of nucleic acids homologous to WTH3 have SEQ ID NOS:7, 10, 11, 24 and 25.

Alternatively, nucleic acid sequences disclosed herein may be used together with the nucleotide sequence of RAB6 to provide nucleic acids which hybridize preferentially to RNA or DNA molecules which have greater or lesser homology to RAB6 than to WTH3. For example, nucleic acid probes which are homologous to RAB6 and not to WTH3 are useful for detection of nucleic acids which are homologous to RAB6 and not WTH3. RAB6c, as disclosed herein, is an example of a gene which displays an overall homology to RAB6, but which possesses one region which is more homologous to WTH3 than to RAB6. It is easy for one of skill in the art to make use of sequences disclosed herein to select or design probes and primers which are capable of hybridizing with WTH3 nucleotides and not RAB6 nucleotides, or capable of hybridizing with RAB6 nucleotides and not WTH3 nucleotides, or capable of hybridizing with both WTH3 nucleotides and RAB6 nucleotides.

According to the present invention, a nucleic acid of the present invention can be labeled by any procedure known in the art to create a probe, for example, by incorporation of nucleotides linked to a "reporter molecule".

A "reporter molecule", as used herein, is a molecule which provides an analytically identifiable signal allowing detection of a hybridized probe. Detection may be either qualitative or quantitative. Commonly used reporter molecules include fluorophores, enzymes, biotin, chemiluminescent molecules, bioluminescent molecules, digoxigenin, avidin, streptavidin or radioisotopes. Commonly used enzymes include horseradish peroxidase, alkaline phosphatase, glucose oxidase and β -galactosidase, among others. Enzymes can be conjugated to avidin or streptavidin for use with a biotinylated probe. Similarly, probes can be conjugated to avidin or streptavidin for use with a biotinylated enzyme. The substrates to be used with these enzymes are generally chosen for the production, upon hydrolysis by the corresponding enzyme, of a detectable color change. For example, p-nitrophenyl phosphate is suitable for use with alkaline phosphatase reporter molecules; for horseradish peroxidase, 1,2-phenylenediamine, 5-aminosalicylic acid or toluidine are commonly used.

Incorporation of a reporter molecule into a DNA probe can be by any method known to the skilled artisan, for example by nick translation, primer extension, random oligo priming, by 3' or 5' end labeling or by other means (see, for example, Sambrook *et al.*).

In another embodiment, the present invention provides one or more compartmentalized kits for detection of hypomethylation, hypermethylation or mutation of nucleic acids homologous to the present WTH3 nucleic acids. The kit has a receptacle containing at least one

of the present probes. Such a probe is capable of hybridizing to DNA sequences at or adjacent to mutated or abnormally methylated WTH3 DNA. Alternatively, a probe can be provided which binds preferentially to DNA sequences at or adjacent to mutated or abnormally methylated RAB6 DNA. The probe provided in the present kits may have a covalently attached reporter molecule.

The present invention further contemplates detecting and isolating nucleic acid homologous to the present WTH3 nucleic acid by nucleic acid amplification. Nucleic acid amplification procedures for use in the present invention include any in vitro amplification procedure which provides sequence-specific synthesis of a nucleic acid fragment relative to the complex bulk of nucleic acid present in a sample. The specificity of the process is determined by enzymatic recognition of a specific sequence or by the oligonucleotide primers which are capable of hybridizing only with the present nucleic acids.

In vitro DNA amplification techniques are known in the art. A review of such techniques can be found in Kwok *et al.*, 8 *Am. Biotechnol. Lab.* 14 (1990). *In vitro* nucleic acid amplification techniques include polymerase chain reaction (PCR), transcription-based amplification system (TAS), self-sustained sequence replication system (3SR), ligation amplification reaction (LAR), ligase-based amplification system (LAS), Q β RNA replication system and run-off transcription.

PCR is a preferred method for DNA amplification. PCR synthesis of DNA fragments occurs by repeated cycles of heat denaturation of DNA fragments, primer annealing onto the adaptor ends of the master-cut DNA fragment, and primer extension. These cycles can be performed manually or, preferably, automatically. Thermal cyclers such as the Perkin-Elmer or Cetus cycler are specifically designed for automating the PCR process, and are preferred. The number of cycles per round of synthesis can be varied from 2 to more than 50, and is readily determined by considering the source and amount of the nucleic acid template, the desired yield and the procedure for detection of the synthesized DNA fragment.

PCR techniques and many variations of PCR are known. Basic PCR techniques are described by Saiki *et al.* (1988 *Science* 239:487-491) and by U.S. Patent Nos. 4,683,195, 4,683,202 and 4,800,159, which are incorporated herein by reference.

The size range of DNA fragments in a sample of genomic DNA is that size range which can be amplified by in vitro DNA amplification. When polymerase chain reaction ("PCR") is used, that size range is about 2000 base pairs (bp) to about 75 bp. Preferably the selected size

range is about 1500 bp to about 100 bp. More preferably the selected size is about 1000 bp to about 150 bp.

The conditions generally required for PCR include temperature, salt, cation, pH and related conditions needed for efficient copying of the master-cut fragment. PCR conditions include repeated cycles of heat denaturation (i.e. heating to at least about 95°C) and incubation at a temperature permitting primer: adaptor hybridization and copying of the master-cut DNA fragment by the amplification enzyme. Heat stable amplification enzymes like the pwo, Thermus aquaticus or Thermococcus litoralis DNA polymerases are commercially available which eliminate the need to add enzyme after each denaturation cycle. The salt, cation, pH and related factors needed for enzymatic amplification activity are available from commercial manufacturers of amplification enzymes.

As provided herein an amplification enzyme is any enzyme which can be used for in vitro nucleic acid amplification, e.g. by the above-described procedures. Such amplification enzymes include pwo, Escherichia coli DNA polymerase I, Klenow fragment of E. coli DNA polymerase I, T4 DNA polymerase, T7 DNA polymerase, Thermus aquaticus (Taq) DNA polymerase, Thermococcus litoralis DNA polymerase, SP6 RNA polymerase, T7 RNA polymerase, T3 RNA polymerase, T4 polynucleotide kinase, Avian Myeloblastosis Virus reverse transcriptase, Moloney Murine Leukemia Virus reverse transcriptase, T4 DNA ligase, E. coli DNA ligase or Q β replicase. Preferred amplification enzymes are the pwo and Taq polymerases. The pwo enzyme is especially preferred because of its fidelity in replicating DNA.

The length of the primers for use in PCR depends on several factors including the nucleotide sequence and the temperature at which these nucleic acids are hybridized or used during in vitro nucleic acid amplification. The considerations necessary to determine a preferred length for an oligonucleotide primer are well known to the skilled artisan. For example, as is known to the skilled artisan, the length of a short nucleic acid or oligonucleotide can relate to its hybridization specificity or selectivity. Because the tester and driver samples contain a complex mixtures of nucleic acids, primers which are shorter than about 12 nucleotides may hybridize to more than one site in the test genomic DNA, and accordingly would not have sufficient hybridization selectivity for amplifying only the master-cut fragments. However, a 12- to 15-nucleotide sequence is generally represented only once in a mammalian genome (Sambrook et al. 1989 Molecular Cloning: A Laboratory Manual, Vol. 2, Cold Spring Harbor Press, Cold Spring Harbor, NY; pp. 11.7-11.8). Accordingly, to eliminate amplification of fragments which

do not have adaptors, primers are chosen which are generally at least about 14 nucleotides long. Preferably, the present primers are at least 16 nucleotides in length. More preferred primers are at least 17 nucleotides in length (Sambrook et al., pp. 11.7- 11.8).

The genomic nucleic acids isolated by the present invention, or oligonucleotides obtained therefrom, can also be used for detecting or measuring expression products, for example, mRNAs, complementary DNAs (cDNAs) and proteins derived from the present genomic nucleic acids and cDNAs. Expression products which may be detected or measured also include those having incomplete homology to the disclosed nucleotide and amino acid sequences.

Expression of mRNAs homologous to the nucleic acids of the present invention may be detected, for example, by Northern analysis, or by reverse transcription and amplification by PCR. Also contemplated are nucleic acid detection and quantification methods which employ signal moieties that are conjugated to nucleic acid probes. Nucleic acids in a sample can be immobilized on a solid support and hybridized to such probes. The signal moiety can be detected directly, for example by fluorescence. Alternatively, the signal moiety may be detected indirectly by its enzymatic activity, for example in an ELISA or other colorimetric assay.

Useful procedures permit detection of mRNAs in a variety of tissue types or at different stages of development. The subject nucleic acids which are expressed in a tissue-specific or a developmental-stage-specific manner are useful as tissue-specific markers or for defining the developmental stage of a sample of cells or tissues. One of skill in the art can readily adapt the present nucleic acids and oligonucleotides for these purposes.

Useful hybridization conditions for probes and primers made according to the present invention are readily determinable by those of skill in the art. Generally, preferred stringent hybridization conditions are those which allow hybridization of nucleic acids which are greater than 90% homologous but which prevent hybridization of nucleic acids which are less than 70% homologous. In situations where nucleic acids belong to families in which extensive homologies exist, it may be desired to further increase stringency of hybridization conditions. Guidelines for predicting melting temperatures of nucleic acid duplexes, whether 100% complementary or containing various numbers of mismatches, are well known in the art. See, e.g. Sambrook et al., 1982 Molecular Cloning: A Laboratory Manual, 388 (Cold Spring Harbor Press, Cold Spring Harbor, NY) and included references.

In another embodiment of the present invention, cDNAs homologous to the present nucleic acids can be isolated by procedures readily available to those of skill in the art. For

example, cDNA libraries can be obtained from the tissues or cells which express the present genomic nucleic acids. Those cDNA libraries can then be probed with a genomic nucleic acid isolated by the methods of the present invention, or an oligonucleotide fragment thereof. Again, one of skill in the art can readily isolate such cDNAs using the genomic nucleic acids of the present invention.

The present genomic and cDNA nucleic acids can be used to prepare oligonucleotides. In one embodiment, oligonucleotides having twelve nucleotides or more can be prepared which hybridize specifically to the present genomic nucleic acids and cDNAs and allow detection and isolation of unique nucleic sequences by hybridization. Sequences of at least 15-20 nucleotides are preferred and are selected from regions which lack homology to other known sequences. Sequences of 20 or more nucleotides which lack such homology are optimal.

Genomic nucleic acids provided by the present invention which include portions of WTH3 (e.g., SEQ ID NOS:7, 10, 11, 13, 14, 15, 16, 17, 18) correspond to a genomic region which is hypermethylated in a drug resistant cell line. Each of these nucleic acids is useful for detecting hypomethylation, hypermethylation and expression of homologous nucleic acids in a variety of normal and cancerous cells or tissues. Each of these nucleic acids is also useful for identifying homologous genomic and cDNA nucleic acids.

Oligonucleotides useful as probes for screening of samples by hybridization assays or as primers for amplification can be packaged into kits. Such kits usually contain the probes or primers in a premeasured or predetermined amount, as well as other suitably packaged reagents and materials needed for the particular hybridization or amplification protocol.

In an embodiment of the invention, nucleic acids of the invention are used to detect expression of WTH3, RAB6C, RAB6 or homologous genes by quantitative PCR. When expression of WTH3 is to be determined, preferred primers are 5'-GATGGAACAATCGGGCTTCG-3' (SEQ ID NO:40) and 5'-GTAGCAGGAACAACCCCTTCG-3' (SEQ ID NO:42). When expression of RAB6C is to be determined, preferred primers are 5'-GATCGAACAATCAGGCTTCAG-3' (SEQ ID NO:43) and 5'-AAGGGGGCCAAAGCAGTGAGC-3' (SEQ ID NO:44). When expression of RAB6 is to be determined, preferred primers are 5'-GGATCGAACAGTACGATTGC-3' (SEQ ID NO:45) and 5'-GCTGCTGCTACACGTCGAAAGAG-3' (SEQ ID NO:46).

In an embodiment of the invention, samples from patients are tested to determine expression of WTH3, RAB6C, RAB6 or a homolog. As used in this context, a homolog is a

nucleic acid sequence which encodes a protein having about 80% or greater amino acid sequence identity to wth3, or rab6c, or rab6 over the length of the protein which corresponds to rab6.

More preferably, a homolog has about 90% or greater sequence identity over the length of the protein which corresponds to rab6. In a preferred embodiment, expression of one or more of these genes is compared to expression of a constitutively expressed gene. Expression of the constitutively expressed gene encoding β -actin is commonly measured for this purpose. Expression of other constitutively expressed genes can be measured instead for this purpose.

In a preferred embodiment, expression of WTH3, or RAB6C, or RAB6, or a homolog in cancer cells is tested. Examples of cancer cells are chronic lymphocytic leukemia (CLL) cells, acute myelogenous leukemia (AML) cells and acute lymphocytic leukemia (ALL) cells.

Expression of any one of these genes is useful as an indication of whether the cancer will be susceptible to treatment with certain drugs. For example, where expression of any one of these genes is reduced two fold with respect to expression in a normal control, resistance to doxorubicin and various other therapeutics which are substantially ineffective for treatment of MDR cancers will be expected and other therapeutics will be used instead. Therapeutics which are substantially ineffective for treatment of MDR cancers include, but are not limited to vinblastin, vincristine, taxol, cis-platin, etoposide, dactinomycin, gramicidin D and 5-fluorouracil. The critical deficiency of expression which differentiates a MDR cell may be larger than two fold. However, it is to be remembered that in a sample of cells from a patient, for example cells from a tumor, or peripheral blood cells, only a small proportion of cells may have acquired drug resistance. A two-fold deficiency in expression from such a sample can indicate that a significant portion of the cancer cells has become resistant to doxorubicin and other drugs.

In another embodiment, the present genomic and cDNA nucleic acids can be placed in expression vectors capable of expressing an encoded protein, polypeptide or peptide. Nucleic acids encoding a desired protein or polypeptide are derived from cDNA or genomic clones using conventional restriction digestion or by synthetic methods, and are ligated into vectors from which they may be expressed. Vectors may, if desired, contain nucleic acids encoding portions of other proteins, thereby providing a fusion protein. For example, portions of the β -galactosidase or superoxide dismutase coding region may be placed in frame with the present coding regions to provide an expression vector which encodes a fusion protein.

Expression vectors include plasmids designed for the expression of proteins or polypeptides fused to or within bacterial phage coat proteins. The DNA encoding the desired protein or polypeptide, whether in a fusion, premature or mature form, may be ligated into expression vectors suitable for any host. The DNA encoding the desired polypeptide may also contain a signal sequence to permit secretion from the intended host. Both prokaryotic and eukaryotic host systems are contemplated.

The present proteins, polypeptides and peptides, whether in a premature, mature or fused form, are isolated from lysed cells, or from the culture medium, and are purified to the extent needed for the intended use. One of skill in the art can readily purify these proteins, polypeptides and peptides by any available procedure. For example, purification may be accomplished by salt fractionation, size exclusion chromatography, ion exchange chromatography, reverse phase chromatography, affinity chromatography and the like.

The present invention further contemplates antibodies which can bind to the present proteins, polypeptides and peptides. Such antibodies preferably bind to unique antigenic regions or epitopes in the present proteins, polypeptides and peptides.

Epitopes and antigenic regions useful for generating antibodies can be found within the present proteins, polypeptides or peptides by procedures available to one of skill in the art. For example, short, unique peptide sequences can be identified in the present proteins and polypeptides that have little or no homology to known amino acid sequences. Preferably the region of a protein selected to act as a peptide epitope or antigen is not entirely hydrophobic; hydrophilic regions are preferred because those regions likely constitute surface epitopes rather than internal regions of the present proteins and polypeptides. These surface epitopes are more readily detected in samples tested for the presence of the present proteins and polypeptides.

Peptides can be made by any procedure known to one of skill in the art, for example, by using in vitro translation or chemical synthesis procedures.

Short peptides which provide an antigenic epitope but which by themselves are too small to induce an immune response may be conjugated to a suitable carrier. Suitable carriers and methods of linkage are well known in the art. Suitable carriers are typically large macromolecules such as proteins, polysaccharides and polymeric amino acids. Examples include serum albumins, keyhole limpet hemocyanin, ovalbumin, polylysine and the like. One of skill in the art can use available procedures and coupling reagents to link the desired peptide epitope to such a carrier. For example, coupling reagents can be used to form disulfide linkages

or thioether linkages from the carrier to the peptide of interest. If the peptide lacks a disulfide group, one may be provided by the addition of a cysteine residue. Alternatively, coupling may be accomplished by activation of carboxyl groups.

The minimum size of peptides useful for obtaining antigen specific antibodies can vary widely. The minimum size must be sufficient to provide an antigenic epitope which is specific to the protein or polypeptide. The maximum size is not critical unless it is desired to obtain antibodies to one particular epitope. For example, a large polypeptide may comprise multiple epitopes, one epitope being particularly useful and a second epitope being immunodominant. Typically, antigenic peptides selected from the present proteins and polypeptides will range from 5 to about 100 amino acids in length. More typically, however, such an antigenic peptide will be a maximum of about 50 amino acids in length, and preferably a maximum of about 30 amino acids. It is usually desirable to select a sequence of about 10, 12 or 15 amino acids, up to a maximum of about 20 or 25 amino acids.

Amino acid sequences comprising useful epitopes can be identified in a number of ways. For example, the entire protein sequence can be screened by preparing a series of peptides that together span the entire protein sequence. One of skill in the art can routinely test a few large polypeptides for the presence of an epitope showing a desired reactivity and also test progressively smaller and overlapping fragments to identify a preferred epitope with the desired specificity and reactivity.

In some situations where a high degree of homology exists among various proteins of a family, useful epitopes will be defined as those which identify one particular member of the protein family, and will correspond to regions of the protein of interest where there is no known homology to other proteins. In those cases, it may be desirable to express only the unique predefined epitopes, for example as part of a fusion protein or displayed on the surface of a filamentous phage particle which can then be used to produce antibodies. Alternatively, monoclonal antibodies can be screened to identify those that bind to the unique epitope and not to epitopes common within the protein family. Similarly, polyclonal antibody preparations may be reacted with other members of the protein family to subtract antibodies which bind to common epitopes.

Antigenic polypeptides and peptides are useful for the production of monoclonal and polyclonal antibodies. To obtain polyclonal antibodies, a selected animal is immunized with a protein or polypeptide. Serum from the animal is collected and treated according to known

procedures. Polyclonal antibodies to the protein or polypeptide of interest may then be purified by affinity chromatography. Techniques for producing polyclonal antisera are well known in the art.

Monoclonal antibodies may be made by procedures available to one of skill in the art, for example, by fusing antibody producing cells with immortalized cells and thereby making a hybridoma. The general methodology for fusion of antibody producing B cells to an immortal cell line is well within the province of one skilled in the art.

The present antibodies are useful for detecting the present proteins and polypeptides in specific tissues or in body fluids. Moreover, according to the present invention, detection of aberrantly expressed proteins or protein fragments is probative of a disease state. For example, expression of the present proteins or polypeptides from a hypomethylated genomic locus may indicate that the protein is being expressed in an inappropriate tissue or at an inappropriate developmental stage. Hence, the present antibodies are useful for detecting diseases associated with protein expression from improperly methylated genomic loci, for example, the types of cancers and genetic diseases contemplated herein.

Design of immunoassays is subject to a great deal of variation and a variety of these are known in the art. Immunoassays may use a monoclonal or polyclonal antibody reagent which is directed against one epitope of the antigen being assayed. Alternatively, a combination of monoclonal or polyclonal antibodies may be used which are directed against more than one epitope. Protocols may be based, for example, upon competition, direct antigen-antibody reaction or sandwich type assays. Protocols may, for example, use solid supports or immunoprecipitation. The present antibodies can be labeled with a reporter molecule for easy detection. Assays which amplify the signal from a bound reagent are also known. Examples include immunoassays which utilize avidin and biotin, or which utilize enzyme-labeled antibody or antigen conjugates, such as ELISA assays.

Kits suitable for immunodiagnosis and containing the appropriate labeled reagents include antibodies directed against the present protein epitopes or antigenic regions, packaged appropriately with the remaining reagents and materials required for the conduct of the assay, as well as a suitable set of assay instructions.

Nucleic acids which are homologous to WTH3, RAB6C, or RAB6 can be useful for treatment of cells and tumors exhibiting multiple drug resistance. For example, drug resistant cells transfected with a vector which expresses WTH3, RAB6C, or RAB6 demonstrate an

increased sensitivity to doxorubicin as compared to cells transfected with a control vector. In MCF7/AdrR cells where multiple transcripts homologous to WTH3, RAB6C, or RAB6 are present in less than normal amounts, multidrug resistance, including resistance to doxorubicin, may not be a direct result of underexpression of WTH3, or of RAB6C, or of RAB6, or of homologs. Nevertheless, increasing expression of any one the genes results in increased sensitivity to doxorubicin. Inhibition of doxorubicin resistance which is observed in cells which overexpress WTH3, RAB6C, or RAB6 is likely to be observed for cells which overexpress homologous genes, as well.

In another embodiment of the invention, a cell which overexpresses wth3, rab6c, rab6 or a homologous protein is used in a screening method which identifies modulators of drug resistance or modulators of multidrug resistance. The cells can also be used to identify modulators of other phenotypes as well. Other useful phenotypes are those which can result from, or be affected by the overexpression of wth3, rab6c, rab6 or a homolog. Useful cells which overexpress the proteins usually contain an expression vector which comprises an exogenous expressible gene which encodes wth3, rab6c, rab6 or a homolog. Alternatively, a cell can be used which has been shown to have increased levels of one or more of the aforementioned proteins. Substances which are modulators of multidrug resistance can exert their effect by increasing expression of wth3, rab6c, rab6 or a homolog from either or both of the endogenous chromosomal gene and the exogenous gene. Alternatively, the modulating substance can affect the protein directly.

To perform such a screening method, the test cell is incubated with an amount of a therapeutic substance to which it would otherwise be tolerant and an amount of the candidate modulator. For example, a cell expressing wth3, rab6c, rab6 or a homolog can be incubated with an amount of doxorubicin which allows continued cell growth and an amount of the test substance. When the therapeutic is doxorubicin, the amount to be used will depend on the test cell. For example, IC_{50} for doxorubicin for MCF7/AdrR cells carrying endogenously expressed RAB6C can be about $1.0 \mu M$ to about $2.5 \mu M$. The concentration of doxorubicin to use would be low enough to allow observable cell growth. It is well known to one of ordinary skill in the art to choose an effective concentration of doxorubicin. Modulators which increase sensitivity of the cells to doxorubicin can be identified by looking for substances which result in cell morbidity. Cells are observed over a period of time and under conditions in which growth of the test cell in the absence of candidate modulator is apparent.

EXAMPLE 1

Altered methylation patterns at CpG dinucleotides in cells exhibiting Multiple Drug Resistance

Methylation sensitive MDD was employed to detect differences in methylation between
DNAs isolated from drug resistant MCF7/AdrR cells (resistant to doxorubin) and the parental
human breast cancer cell line MCF7.

Isolation of a hypermethylated DNA fragment from MCF7 human breast cancer cell line.

DNAs isolated from MCF7/AdrR and MCF7 cell lines (available from National Institutes of
Health, Bethesda, MD) were cleaved by the *Hpa* II enzyme. To study DNA hypermethylation
events, cleaved MCF7 DNA was used as tester, while cleaved MCF7/AdrR was used as driver.
1 μ g of DNA tester and driver were cleaved with *Hpa* II (20 U/ μ g) (Boehringer Mannheim) in a
200 μ l reaction for 3 hours. To prepare tester and driver amplicons, the digested tester and
driver DNAs were ligated to MSA24-mer (SEQ ID NO:1) and MSA12-mer (SEQ ID NO:2).
The procedures for amplicon preparation were as described in N.A. Lisitsyn et al., *Direct
Isolation of Polymorphic Markers Linked to a Trait by Genetically Directed Representational
Difference Analysis*, 6 NATURE GENETICS 57 (1994). The DNA amplicons were then purified by
phenol, phenol/chloroform extraction. To remove the first set of linkers from the driver
amplicon, 80 μ g of driver amplicon DNA was digested with the *Hpa* II enzyme (10 U/ μ g). To
change the tester amplicon DNA linkers, 5 μ g of tester amplicon was digested with *Hpa* II (10
U/ μ g), and ligated to MSB24-mer (SEQ ID NO:3), and MSB12-mer (SEQ ID NO:4), a second
set of oligonucleotide linkers. Subtractive hybridization was performed, followed by
Polymerase Chain Reaction (PCR) amplification of the first round difference products (DP1)
which was carried out as described in Lisitsyn, N. et al. (1994). To prepare the second round of
subtractive hybridization, 3 μ g of DP1 was digested with the restriction endonuclease *Hpa* II (10
U/ μ g), and ligated to third set of linkers, MSC24-mer (SEQ ID NO:5) and MSC12-mer (SEQ ID
NO:6). Another round of subtractive hybridization/PCR amplification was performed. The
second difference product (DP2) was amplified as before. The individual DNA fragments in
DP2 were purified by DNA gel extraction kit (Qiagen Inc.), ligated into plasmid vector pUC118
linearized by the restriction endonuclease *Acc* I, and transformed into *E. coli* (DH5 α). Plasmid
DNAs were isolated from twelve colonies, and served as templates to amplify the inserts by
PCR. Different sized inserts were selected as probes for amplicon Southern analysis. The
candidate probes were further tested by genomic DNA Southern analysis.

Amplicon DNA Southern analysis. A candidate probe was identified which hybridized to tester amplicon DNA but not to driver amplicon DNA. The first screen for identification of candidate probes was performed with amplicon DNA Southern blots. A non-Radiation DIG Labeling and Detection Kit was purchased from Boehringer Mannheim. Probe labeling, and detection followed the instructions of the manufacturer. 2 μ g of tester and driver amplicon DNA were electrophoresed on a 2% agarose gel, and blotted to positively charged nylon membranes (Boehringer Mannheim). For prehybridization the membranes were placed at 68°C for 2-4 hours in solutions containing 5 X SSC, 0.1% of N-lauroylsarcosine, 0.02% of SDS, 1% of blocking reagent. Under the same conditions, the probes were added, and hybridized to the membranes overnight. The membranes were then rinsed with 2 X SSC, 0.1% SDS for 5 min twice at room temperature, then washed twice with 0.1 X SSC, 0.1% SDS for 15 min at 68°C. Next, the membranes were equilibrated in maleic acid buffer (0.1 M maleic acid, 0.15 M NaCl, pH 7.5) then transferred into blocking solution (1% black reagent in maleic acid buffer) and incubated at room temperature for 30 min. The membranes were then incubated for 30 min in antibody solution (75 mU/ml of anti-DIG-AP conjugate in blocking solution). After the membranes were equilibrated 2-5 min in detection buffer (0.1 M Tris-HCl, 0.1 M NaCl, 50 mM MgCl₂, pH 9.5), the color was developed in freshly prepared color solution (45 μ l NBT solution, 35 μ l X-phosphate solution in 10 ml of detection buffer). When the desired color intensities were achieved, the reaction was stopped by washing the membranes with 50 ml of water for 5 min. A probe designated *WTH3* was identified which hybridized only to tester amplicon DNA.

Genomic DNA Southern analysis. The candidate probes confirmed by amplicon DNA Southern blot experiments was further tested by MCF7/AdrR and MCF7 genomic DNA Southern blotting. 6 μ g of genomic DNA was digested with *Hpa* II (20 U/ μ g) for 4 hours, and electrophoresed on a 1% agarose gel. Digested DNA was then transferred to a Hybond N-membranes (Amersham, Arlington Heights, IL) which were then exposed to UV light to immobilize the DNA. The probe for the Southern blot was labeled using a High Prime DNA labeling kit (Boehringer Mannheim) following the instructions of the manufacturer. For prehybridization, the membranes were placed at 68°C for 2-4 hours in solutions containing 6 X SSC, 5 X Denhardt's solution, 0.5% SDS, 0.1 M EDTA, and 50 μ g/ml of salmon sperm DNA. Under the same conditions, probe was added, and hybridized to the membranes overnight. The membranes were then rinsed three times with 2 X SSC, 1 X Blot wash (12 mM Na₂HP0₄, 8 mM

NaH₂PO₄, 1.4 mM Na₄P₂O₇, 0.5% SDS) at 68°C, and further washed three times (30 minutes each) with the same buffer at 68°C. The membranes were exposed on Kodak X-OMAT films overnight.

The Southern blot results showed that probe *WTH3* hybridized an approximately 600 bp length single band in the MCF7 DNA but not in the MCF7/AdrR DNA. However, at this point, we could not conclude that the differences observed were caused by differential DNA methylation in the two cell lines, since similar hybridization patterns could be the results of either DNA point mutations or deletions. To identify the cause, Southern analysis was performed on both genomic DNAs which were digested by the *Msp* I enzyme. *Msp* I is an isoschizomer of *Hpa* II, although it is not sensitive to CmCGG. Therefore, *Msp* I could cleave a methylated site which could not be cut by *Hpa* II. The results showed that probe *WTH3* detected the same hybridization patterns: a single, 600 bp length band appeared in both DNAs. This result suggested that the difference detected by probe *WTH3* in the *Hpa* II digested DNAs represented a hypermethylation event rather than a nucleotide mutation or DNA deletion.

WTH3 is a homolog of the known human gene RAB6 and is located in the q31 region of chromosome 2. The pUC118 plasmid containing the *WTH3* probe was sequenced using the Ampli-Cycle sequencing kit (Perkin-Elmer), under conditions described by the manufacturer. Chromosome assignment was determined with Genebridge 4 Radiation Hybrid Panel (Research Genetics, Inc.) by PCR.

DNA sequence analysis showed that probe *WTH3* contains 573 nucleotides with both ends terminating in *Hpa* II recognition sites (SEQ ID NO:7). The sequence indicates a gene sequence encoding 175 amino acids and a 47 bp untranslated region at the 5' end. A homology search of the NIH GenBank indicated that the encoded polypeptide shares 89% identity with the first 175 amino acids of the human rab6 protein (GenBank Accession No. M28212), a guanosine triphosphatase (GTPase) containing 208 amino acids. We assume that a 3' end of WTH3 was cut off by digestion with *Hpa* II. The overall nucleotide sequence homology between the WTH3 genomic clone and RAB6 is high, with sequence differences concentrated within a central region which corresponds to about amino acid 62 through about amino acid 91 of the encoded protein, as shown in Fig. 1.

The 3' end of WTH3 was obtained by a rapid amplification of cDNA ends (RACE) protocol, modified according to Chen, Z., *Simple modifications to increase specificity of the 5'*

RACE procedure, 12 TRENDS GENET 87 (1996). Two WTH3 specific primers, W3/Race1 (5'-GATGGAACAATCGGGCTTCG-3'; SEQ ID NO:40) and W3/Race2 (5'-AAACAGTCAGCGAAGGGGGT-3'; SEQ ID NO:41) were used in sequential RACE reactions. The nucleotide sequence obtained for the WTH3 locus is represented by SEQ ID NO:10. The coding sequence is represented by SEQ ID NO:11. The gene encodes a protein of 254 amino acids which is represented by SEQ ID NO: 12. The homology between the encoded protein and human rab6 is shown in Fig. 2.

The chromosome assignment of WTH3 was determined by amplification from a human genomic DNA library (GENEBRIDGE 4 RH Panel, Research Genetics, Inc.) and the human genome radiation hybrid map of the Whitehead Institute/MIT Center for Genome Research using primers designed to avoid regions of homology between WTH3 and RAB6. One PCR primer (bottom) was designed based on the nonhomologous region located in the middle of the WTH3 gene sequence. The top and bottom strand primer sequences are:
5'-TCCTCTAGTTCCACCATGTCCAC-3' (SEQ ID NO:8) and
5'-CACAGCCGAAGCCCGATTG-3' (SEQ ID NO:9). The map position for WTH3 is 2q31 on the long arm of chromosome 2. The adjacent Sequence Tagged Site (STS) is CHLC.GATA27A12.

Isolation of cDNA and full length coding sequences of WTH3 and RAB6C. The 573 nucleotide *WTH3* probe was used to screen cDNA libraries produced from human kidney cells (courtesy of Dr. M. Wigler) and white cell leukemia cells (CLONTECH). Sequence analysis of a number of overlapping clones yielded a composite cDNA sequence of 1460 bp (SEQ ID NO:25). This cDNA has been designated RAB6C. Fig. 3 shows the homology between RAB6C and RAB6. The encoded protein consists of 208 amino acids and differs from the rab6 protein at 3 positions (Fig. 4). Notably, the nucleotide sequence differences between RAB6C and RAB6 are concentrated within the same central region as are the nucleotide sequence differences between WTH3 and RAB6 as disclosed in Fig. 1, which corresponds to about amino acid 62 through about amino acid 91 of the encoded protein.

EXAMPLE 2

Expression of WTH3 and homologs.

Northern analysis. Total RNA was isolated from MCF7/AdrR and MCF7 cell lines by RNA isolation kit, RNA STAT-60, manufactured by TEL-TEST, Inc. 20 μ g of RNA from each cell line was electrophoresed on 1% RNA agarose gels, and then transferred to Hybond N-membranes (Amersham, Arlington Heights, IL). The membrane was baked in a vacuum oven at 80°C for 2 hours to immobilize the RNA. The probes for the northern blot were also labeled with High Prime DNA labeling kits. The procedure for hybridization and blot wash were the same as in the genomic DNA Southern analysis.

Expression of WTH3 is reduced in the MCF7/AdrR cells relative to MCF7 cells. Levels of gene expression of WTH3 in MCF7 and MCF7/AdrR cells were examined by northern analysis. A probe was prepared from the previously described WTH3 containing pUC118 plasmid using primers M13 (5'-GTAAAACGACGGCCAGT-3'; SEQ ID NO:29) and AS (5'-AGCGGATAACAATTTACACAGGA-3'; SEQ ID NO:30). A probe consisting of a cDNA fragment of the ubiquitously expressed β -actin gene was used as an endogenous control.

The results showed that *WTH3* hybridized a 3 kb length band in RNA isolated from both MCF7/AdrR and MCF7 cells. However, the expression level in the MCF7/AdrR cells was about ten times less than that in the MCF7 cells when they were compared to the expressed house keeping gene, β -actin, which hybridized a 2 kb length band in both RNAs (Fig. 5). These results demonstrated that DNA hypermethylation coincided with inhibition of WTH3 gene expression in the MCF7/AdrR cells.

Expression of WTH3 is reduced in peripheral blood cells of leukemia patients. mRNA was prepared from peripheral blood samples from patients having chronic lymphocytic leukemia (CLL), acute myelogenous leukemia (AML), and acute lymphocytic leukemia (ALL). Expression of WTH3 mRNA was determined by quantitative PCR and compared to expression of a constitutively express control mRNA (β -actin). In 6 CLL patients, WTH3 expression was reduced 4 to 100 times as compared to a normal control. In 7 AML patients, expression of WTH3 was reduced 20 to 100 times. In 3 ALL patients, expression of WTH3 was reduced 25 to

100 times. Overall, the amount of decrease in expression was correlated with the severity of the disease and the survival rate of the patients.

Expression of RAB6 related genes is reduced in MDR cells. Expression of RAB6C was determined by two methods. First, northern analysis was used to compare RNA isolated from MCF7/AdrR cells with RNA isolated from MCF7 cells. A 208 bp *RAB6* probe consisting of bases 56 to 263 of RAB6 (GenBank Accession No. M28212) was amplified from a cloned fragment using sense and antisense primers 5'-TCCTCTAGTTCCACAATGTCC-3' (SEQ ID NO:31) and 5'-GCAATCGTACTGTTTCGATC-3' (SEQ ID NO:32). In order for a quantitative comparison to be made between MCF7/AdrR cells and MCF7 drug sensitive cells, a second probe was prepared which hybridized to glyceraldehyde-3-phosphate dehydrogenase (GPDH). The GPDH probe was amplified using primers 5'-CGGAGTCAACGGATTTGGTCGTAT-3' (SEQ ID NO:33) and 5'-AGCCTTCTCCATGGTGGTGAAGAC-3' (SEQ ID NO:34). Surprisingly, a series of different sized RNA species was detected in both RNA preparations (Fig. 6). Equally surprising was the fact that the amount of each transcript detected was reduced in preparations from MCF7/AdrR cells relative to MCF7 cells. The intensities of the resulting bands on the exposed northern blot were quantitatively measured by densitometry and normalized according to the band corresponding to GPDH mRNA. The amount of RAB6 mRNA present in MCF/AdrR drug resistant cells was determined to be approximately 15 times less than in normal MCF7 cells.

Quantitative RT-PCR was then performed using primers specific either for RAB6 or RAB6C. In both cases, β -actin mRNA was also measured and used to normalize results obtained with MCF7/AdrR drug resistant cells and MCF7 drug sensitive cells. The primers used to amplify RAB6 sequences were 5'-GCTGAGGAAATTCAAGCTGG-3' (SEQ ID NO:35) and 5'-CAACAACTGCCACAGTGGAGTC-3' (SEQ ID NO:36). The primers used to amplify RAB6C sequences were 5'-GCTGAGGAAATTCAAGCTGG-3' (SEQ ID NO:35) and 5'-CTACTACAGCTGCAGCAGAATC-3' (SEQ ID NO:37). β -actin sequences were amplified using primers 5'-ACGACATGGAGAAGATCTGGC-3' (SEQ ID NO:38) and 5'-TTCTCGATGCTCGACGGGCTACC-3' (SEQ ID NO:39). The amounts of RT-PCR products were quantitatively determined by densitometry. The amount of RAB6 mRNA was reduced about 9-fold in MCF7/AdrR drug resistant cells relative to MCF7 drug sensitive cells.

Similarly, the amount of RAB6C mRNA was reduced about 7-fold in MCF7/AdrR cells relative to MCF7 cells.

EXAMPLE 3

Exogenous expression of WTH3, RAB6C and RAB6

Reversion of MDR phenotype by overexpression of WTH3, RAB6 or RAB6C in MCF7/AdrR cells. WTH3, RAB6 and RAB6C cDNAs were inserted into pcDNA1.1/Amp expression vectors (Invitrogen Corp.) and transfected into drug resistant MCF7/AdrR cells (Lipofect Amine Plus™; Life Technologies, Inc., (GIBCO)). Expression of the exogenous WTH3 (pcDNA/WTH3), RAB6 (pcDNA/RAB6) or RAB6C (pcDNA/RAB6C) genes in transfected cells was confirmed by RT-PCR. Control cells were provided by transfection with pcDNA1.1/Amp which contained no insert. Cells were exposed to various concentrations of doxorubicin and viability was determined after 72 hours by MTT assay. Cells expressing endogenous WTH3 were shown to have increased sensitivity to doxorubicin and vincristine. Cells expressing RAB6 or RAB6C cDNAs were tested for sensitivity to doxorubicin. Mean IC₅₀ ± SD values were 4.93 ± 0.30 μM for control cells, 2.23 ± 0.17 μM for pcDNA/RAB6 containing cells, and 1.53 ± 0.13 μM for pcDNA/RAB6C containing cells. The drug resistant control cells were 3.2 (P<0.0001) times more resistant to the antitumor drug than pcDNA/RAB6C containing cells and 2.2 (P<0.0001) times more resistant to the antitumor drug than pcDNA/RAB6 containing cells.

Doxorubicin Efflux. Retention of doxorubicin was analyzed by flow cytometry in load/chase experiments. Approximately 5 x 10⁴ cells per well in 6 well dishes were loaded with 30 μg/ml doxorubicin in 1 ml of culture media for 2 hr. at 37°C. The culture media was chased with fresh media containing no doxorubicin. At various times (0, 3, and 5 hr.) following the chase, the media was removed, and the cells were washed twice in PBS and trypsinized. Cells were centrifuged at 1000 x g for 5 min. and resuspended in 300 μl of 1% paraformaldehyde. The doxorubicin content was determined by flow cytometry as described by Doyle, et al., *Expression of a 95 kDa membrane protein is associated with low daunorubicin accumulation in leukaemic blast cells*, 71 BR. CANCER J. 52 (1995). Control cells demonstrated a significant loss of fluorescence after 3 hours of chase and a further loss after 5 hours (Fig. 8a). In comparison, after 3 hours of chase, both pcDNA/RAB6C (Fig. 8b) and pcDNA/RAB6 (Fig. 8c) containing cells retained fluorescence and continued to retain fluorescence after 5 hours of chase.

Fluorescence microscopy confirmed retention of doxorubicin by pcDNA/RAB6 and pcDNA/RAB6C containing cells after a 6 hour chase (Fig. 9). Approximately 5×10^4 MCF7/AdrR cells transfected with pcDNA/RAB6, pcDNA/RAB6C, or pcDNA1.1/Amp were cultured in 6 well dishes. Cells were loaded with $30 \mu\text{g/ml}$ doxorubicin in media for 2 hours.

5 The media was removed and the cells were washed with PBS, followed by the addition of fresh media without doxorubicin (chase). Cells were examined for fluorescence at 488nm at the end of the loading period and after 6 hours of chase). After 6 hours of chase, only cells transfected with RAB6 (Fig. 9H) and RAB6C (Fig. 9J) continued to fluoresce. At this point, control cells (Fig. 9M) showed no fluorescence. The control cells were healthy and continued to divide
10 following the chase. These results are consistent with the increases sensitivity to doxorubicin demonstrated above.

We claim:

1. An isolated nucleic acid comprising a sequence encoding a wth3 protein.
2. The nucleic acid of Claim 1 which encodes the amino acid sequence comprising SEQ ID NO:12 from about amino acid residue number 1 to about amino acid residue number 254.
3. The nucleic acid of Claim 1 which comprises the nucleotides of SEQ ID NO:11.
4. An isolated nucleic acid encoding an immunogenic fragment of wth3 having from 7 to 25 contiguous amino acid residues of SEQ ID NO:12 and comprising at least 3 amino acid residues of SEQ ID NO:19 or SEQ ID NO:20 or SEQ ID NO:21 or SEQ ID NO:22 or SEQ ID NO:23 or SEQ ID NO:24.
5. An isolated nucleic acid comprising a sequence encoding the amino acid sequence of SEQ ID NO:27 from about amino acid residue number 1 to about amino acid residue number 208.
6. The nucleic acid of Claim 5 which comprises SEQ ID NO:26.
7. A recombinant DNA comprising the nucleic acid of any one of Claims 1 to 6 operably linked to regulatory control nucleic acid sequences which can effect expression of said nucleic acid sequence in a host cell.
8. An expression vector comprising the recombinant DNA of Claim 7.
9. A host cell comprising the expression vector of Claim 8.
10. The host cell of Claim 9 wherein said host cell is a eukaryotic or prokaryotic cell.
11. A method of producing a recombinant wth3 protein or immunogenic fragment thereof, which process comprises:
 - a) culturing the host cell of Claim 9 in a culture medium under conditions suitable for expression of the wth3 protein or immunogenic fragment thereof in said host cell, and
 - b) recovering said recombinant protein or immunogenic fragment thereof from said host cell or said culture medium.
12. A wth3 protein or immunogenic fragment thereof prepared by the method of Claim 11.
13. A substantially purified protein comprising wth3.
14. A substantially purified immunogenic fragment of wth3 having 7 to 25 contiguous amino acid residues of SEQ ID NO:12 and comprising at least 3 amino acid residues of SEQ ID

NO:19 or SEQ ID NO:20 or SEQ ID NO:21 or SEQ ID NO:22 or SEQ ID NO:23 or SEQ ID NO:24.

15. A substantially purified protein or polypeptide comprising the immunogenic fragment of Claim 14.

16. A substantially purified immunogenic fragment of wth3 capable of generating antibodies which bind to wth3 and not to rab6.

17. A substantially purified protein comprising SEQ ID NO:27 from about amino acid residue number 1 to about amino acid residue 208.

18. An isolated nucleic acid comprising a sequence of at least about 15 nucleotides of SEQ ID NO: 10 which is capable of hybridizing to a nucleic acid segment of a WTH3 gene under stringent hybridization conditions wherein said nucleic acid fails to hybridize to a nucleic acid segment of a RAB6 gene.

19. The isolated nucleic acid of Claim 18 which comprises at least 20 adjacent nucleotides of SEQ ID NO:10.

20. The isolated nucleic acid of Claim 18 which comprises SEQ ID NO:7 from about nucleotide number 1 to about nucleotide number 573.

21. An antibody which binds selectively to wth3 protein wherein the affinity of said antibody for wth3 protein is greater than the affinity of said antibody for rab6 protein.

22. A method of producing a hybridoma which secretes an antibody that binds to wth3 protein wherein the affinity of said antibody for wth3 protein is greater than the affinity of said antibody for rab6 protein, which comprises:

- a) immunizing an animal with wth3 protein or a polypeptide fragment thereof;
- b) obtaining lymphoid cells from the immunized animal;
- c) fusing the lymphoid cells and an immortalizing cell to produce hybrid cells; and
- d) selecting hybrid cells which produce antibody that:
 - i) specifically binds to wth3 protein; and
 - ii) binds to rab6 protein with an affinity that is lower than the affinity of said antibody for wth3 protein.

23. A method for identifying wth3 protein in a test sample, which comprises contacting the test sample with an anti-wth3 antibody or fragment thereof that specifically binds to wth3 protein with an affinity that is greater than the affinity of said antibody for rab6 protein and forms a complex therewith.

24. The method of claim 23 which further comprises contacting a control sample with said anti-wth3 antibody or fragment thereof.

25. A method for identifying wth3 protein in a test sample, which comprises

- a) contacting the test sample with a first anti-wth3 antibody under conditions such that wth3 protein binds to said first antibody and forms a complex therewith;
- b) contacting the test sample with a second anti-wth3 antibody that specifically binds to wth3 protein such that a second complex is formed therewith;
- c) contacting the complex formed in step (b) with an indicator reagent comprising a signal generating compound and capable of binding to said first or second anti-wth3 antibody; and
- d) detecting the signal generating compound, thus detecting the wth3 protein

wherein at least one of said first and said second anti-wth3 antibodies binds to wth3 protein with an affinity that is greater than the affinity of said antibody for rab6 protein.

26. A kit for the specific assay of wth3 protein in a test sample comprising an antibody or antibody fragment capable of binding specifically to wth3 protein with an affinity that is greater than the affinity of said antibody or antibody fragment for rab6 protein.

27. A method for detecting whether a DNA sequence is hypomethylated or hypermethylated in the region of genomic DNA which comprises WTH3 that is present in a test sample of cells which comprises:

- a) cleaving genomic DNA isolated from said test sample of cells with a master restriction enzyme to generate a cleaved test-cell DNA;
- b) hybridizing a probe to said cleaved test-cell DNA to form a hybridization complex, wherein said probe comprises a nucleic acid which hybridizes to a region of said test-cell DNA which is adjacent to said DNA sequence; and
- c) determining the size of the hybridization complex;

wherein said master restriction enzyme cleaves a nonmethylated DNA sequence but does not cleave a methylated DNA sequence.

28. The method of claim 27 wherein said region of genomic DNA which comprises WTH3 is within 10 kb of the transcribed WTH3 sequence.

29. The method of claim 27 which further comprises:

- a) cleaving genomic DNA isolated from a control sample of cells with said master restriction enzyme to generate a cleaved control-cell DNA;

- b) hybridizing said probe to said cleaved control-cell DNA to form a control-hybridization complex; and
- c) determining the size of the control-hybridization complex.

30. A kit for identifying whether a DNA sequence in a test sample is hypomethylated or hypermethylated in the region of genomic DNA which comprises WTH3, said kit comprising a nucleic acid hybridization assay probe capable of forming a detectable hybrid with WTH3 DNA and not with RAB6 DNA under stringent hybridization conditions.

31. A method for detecting WTH3 mRNA in a test sample which comprises:

- a) contacting test sample RNA with a nucleic acid probe which is capable of forming a hybrid with WTH3 mRNA, and
- b) detecting nucleic acid probe-WTH3 mRNA hybrids;

wherein said mRNA and said probe are contacted under stringent hybridization conditions selected to prevent hybridization of said probe to RAB6 mRNA.

32. The method of claim 31 which further comprises detecting WTH3 mRNA in a control sample.

33. The method of claim 31 which further comprises:

- a) contacting said test sample RNA with a second nucleic acid probe which is capable hybridizing to RNA which is constitutively expressed; and
- b) comparing said WTH3 mRNA-nucleic acid probe hybrids with constitutively expressed-second nucleic acid probe hybrids.

34. A kit for detecting WTH3 mRNA in a test sample, which comprises a nucleic acid hybridization probe capable of forming a detectable hybrid with WTH3 mRNA under stringent hybridization conditions selected to prevent hybridization of said probe to RAB6 mRNA.

35. The kit of claim 34 which further comprises a control RNA having a known amount of WTH3 mRNA.

36. The kit of claim 34 which further comprises a nucleic acid probe capable of forming a detectable hybrid with constitutively expressed RNA.

37. A method for detecting WTH3 mRNA in a test sample, which comprises making cDNA from said WTH3 mRNA and detecting said cDNA, wherein RAB6 mRNA is not detected.

38. The method of claim 37 which further comprises detecting WTH3 mRNA in a control sample.

39. The method of claim 37 which further comprises detecting constitutively expressed RNA in said test sample and comparing said WTH3 mRNA with said constitutively expressed RNA.

40. The method of claim 37 wherein detection of said cDNA comprises an amplification reaction.

41. A kit for detecting WTH3 mRNA comprising an oligonucleotide capable of hybridizing to WTH3 mRNA in a test sample and priming reverse transcription of WTH3 cDNA and comprising primers capable of amplifying said WTH3 cDNA, wherein RAB6 mRNA is not detected.

42. A method for detecting whether a DNA sequence is hypomethylated or hypermethylated in the region of genomic DNA which comprises RAB6 that is present in a test sample of cells which comprises:

- a) cleaving genomic DNA isolated from said test sample of cells with a master restriction enzyme to generate a cleaved test-cell DNA;
- b) hybridizing a probe to said cleaved test-cell DNA to form a hybridization complex, wherein said probe comprises a nucleic acid which hybridizes to a region of said test-cell DNA which is adjacent to said DNA sequence; and
- c) determining the size of the hybridization complex;

wherein said master restriction enzyme cleaves a nonmethylated DNA sequence but does not cleave a methylated DNA sequence.

43. The method of claim 42 wherein said region of genomic DNA which comprises RAB6 is within 10 kb of the transcribed RAB6 sequence.

44. The method of claim 42 which further comprises:

- a) cleaving genomic DNA isolated from a control sample of cells with said master restriction enzyme to generate a cleaved control-cell DNA;
- b) hybridizing said probe to said cleaved control-cell DNA to form a control-hybridization complex; and
- c) determining the size of the control-hybridization complex.

45. A kit for identifying whether a DNA sequence in a test sample is hypomethylated or hypermethylated in the region of genomic DNA which comprises RAB6, said kit comprising a nucleic acid hybridization assay probe capable of forming a detectable hybrid with RAB6 DNA and not WTH3 DNA under stringent hybridization conditions.

46. A method for measuring RAB6 mRNA in a test sample which comprises:
- a) contacting said test sample RNA and control RNA with a nucleic acid probe which is capable of forming a hybrid with RAB6 mRNA; and
 - b) comparing test sample RNA-nucleic acid probe hybrids and control RNA-nucleic acid hybrids.
47. A method for measuring RAB6 mRNA in a test sample which comprises:
- a) contacting said test sample RNA with a first nucleic acid probe which is capable of forming a hybrid with RAB6 mRNA;
 - b) contacting said test sample RNA with a second nucleic acid probe which is capable of forming a hybrid with RNA which is constitutively expressed; and
 - c) comparing test sample RNA-first nucleic acid probe hybrids with constitutively expressed RNA-second nucleic acid probe hybrids.

48. A kit for measuring RAB6 mRNA in a test sample, which comprises a first nucleic acid hybridization probe capable of forming a detectable hybrid with RAB6 mRNA under stringent hybridization conditions, and

- i) a second nucleic acid hybridization probe capable of forming a detectable hybrid with constitutively expressed RNA, or
- ii) a control RNA.

49. A method for measuring RAB6 mRNA in a test sample, which comprises making cDNA from said RAB6 mRNA, and;

- i) making cDNA from constitutively expressed RNA in said test sample, or
- ii) making cDNA from RAB6 mRNA in a control sample;

and comparing said cDNAs.

50. The method of claim 49 wherein comparing said cDNAs comprises an amplification reaction.

51. A kit for measuring RAB6 mRNA in a test sample, said kit comprising a first oligonucleotide capable of hybridizing to RAB6 mRNA and priming reverse transcription of cDNA, and;

- a) a second oligonucleotide capable of hybridizing to a constitutively expressed RNA and priming reverse transcription of cDNA, or
- b) a control RNA.

52. A method for detecting mRNA having homology to WTH3 in a test sample which comprises:

- a) contacting test sample RNA with a nucleic acid probe which is capable of forming a hybrid with WTH3 mRNA; and
- b) detecting nucleic acid probe-WTH3 homolog mRNA hybrids

wherein said mRNA and said probe are contacted under stringent hybridization conditions selected to prevent hybridization of said probe to RAB6 mRNA.

53. The method of claim 52 which further comprises detecting mRNA having homology to WTH3 in a control sample.

54. The method of claim 52 which further comprises:

- a) contacting said test sample RNA with a second nucleic acid probe which is capable of hybridizing to RNA which is constitutively expressed;
- b) comparing said WTH3 homolog mRNA-nucleic acid probe hybrids with constitutively expressed RNA-second nucleic acid probe hybrids.

55. A kit capable of detecting mRNA homologous to WTH3 in a test sample, which comprises a nucleic acid hybridization probe capable of forming a detectable hybrid with WTH3 mRNA under stringent hybridization conditions selected to prevent hybridization of said probe to RAB6 mRNA.

56. The kit of claim 55 which further comprises a control RNA having a known amount of WTH3 mRNA.

57. The kit of claim 55 which further comprises a nucleic acid probe capable of forming a detectable hybrid with constitutively expressed RNA.

58. A method for detecting mRNA homologous to WTH3 in a test sample, which comprises making cDNA from said mRNA and detecting said cDNA, wherein RAB6 mRNA is not detected.

59. The method of claim 58 which further comprises detecting mRNA homologous to WTH3 in a control sample.

60. The method of claim 58 which further comprises detecting constitutively expressed RNA in said test sample and comparing said mRNA homologous to WTH3 with said constitutively expressed RNA.

61. The method of claim 58 wherein detection of said cDNA comprises an amplification reaction.

62. A kit for detecting mRNA homologous to WTH3 comprising an oligonucleotide capable of hybridizing to WTH3 mRNA in a test sample and priming reverse transcription of WTH3 cDNA and comprising primers capable of amplifying WTH3 cDNA, wherein RAB6 mRNA is not detected.

63. A method for measuring mRNA having homology to RAB6 in a test sample which comprises:

- a) contacting test sample RNA and control RNA with a nucleic acid probe which is capable of forming a hybrid with RAB6 mRNA; and
- b) comparing test sample RNA-nucleic acid probe hybrids and control RNA-nucleic acid hybrids.

64. A method for measuring mRNA homologous to RAB6 in a test sample which comprises:

- a) contacting said test sample RNA with a first nucleic acid probe which is capable of hybridizing to RAB6 mRNA;
- b) contacting said test sample RNA with a second nucleic acid probe which is capable of hybridizing to RNA which is constitutively expressed; and
- c) comparing test sample RNA-first nucleic acid hybrids with constitutively expressed RNA-second nucleic acid hybrids.

65. A kit for measuring mRNA homologous to RAB6 in a test sample, which comprises a first nucleic acid hybridization probe capable of forming a detectable hybrid with RAB6 mRNA under stringent conditions, and

- i) a second nucleic acid hybridization probe capable of forming a detectable hybrid with constitutively expressed RNA, or
- ii) a control RNA.

66. A method for measuring mRNA homologous to RAB6 in a test sample which comprises making cDNA from said mRNA, and;

- a) making cDNA from constitutively expressed RNA in said test sample, or
 - b) making cDNA from mRNA homologous to RAB6 in a control sample;
- and comparing said cDNAs.

67. The method of claim 66 wherein comparing said cDNAs comprises an amplification reaction.

68. A kit for measuring mRNA homologous to RAB6 in a test sample, which comprises a first oligonucleotide capable of hybridizing to RAB6 mRNA and priming reverse transcription of cDNA, and;

- a) a second oligonucleotide capable of hybridizing to a constitutively expressed RNA and priming reverse transcription of cDNA, or
- b) a control RNA.

69. A method for increasing drug sensitivity in a multiply drug resistant cell which comprises insertion of a nucleic acid comprising WTH3, RAB6C or RAB6 and expression thereof.

70. A recombinant expression vector suitable for increasing drug sensitivity in a multiply drug resistant host cell comprising a nucleotide as claimed in Claim 1 or Claim 5 and a regulatory sequence operatively linked to the nucleic acid.

71. A method of determining the suitability of a therapeutic for treatment of a cancer, wherein the therapeutic is substantially ineffective for treatment of cells which have acquired multidrug resistance, which comprises:

providing a test sample from the cancer;

measuring expression of WTH3 mRNA, or RAB6C mRNA, or RAB6 mRNA, or a homologous mRNA in the test sample;

comparing expression of the mRNA in the test sample with expression of the mRNA in a control sample; and

determining whether expression of the mRNA in the test sample is reduced relative to expression of the mRNA in the control sample.

72. The method of Claim 71 wherein the therapeutic substance is doxorubicin.

73. The method of Claim 71 wherein the therapeutic substance is vincristine.

74. The method of Claim 71 wherein the cancer is a leukemia.

75. The method of Claim 71 wherein the control sample is from doxorubicin sensitive cells.

76. The method of Claim 71 wherein the control sample is from MCF7 cells.

77. A method for determining whether a substance increases sensitivity of a cell to a therapeutic which comprises:

providing a test cell which overproduces wth3 or rab6c or rab6 or a homolog thereof;

incubating the substance with the test cell and the therapeutic; and
comparing the response of the test cell in the presence of the therapeutic and the substance to the response of the test cell in the presence of the therapeutic and the absence of the substance.

78. The method of Claim 77 wherein the therapeutic is an anti-cancer drug.

79. The method of Claim 77 wherein the therapeutic is substantially ineffective for treatment of cells which have acquired multidrug resistance.

80. The method of Claim 77 wherein the therapeutic is doxorubicin.

ABSTRACT

The present invention provides genomic loci which are hypermethylated and differentially expressed in drug resistant cells compared to non-drug resistant cells. These genomic loci are homologous to the rab6 locus but map to a different chromosomal position.

5 The present invention also provides nucleic acids isolated from these genomic loci by Methyl-Differential Display (MDD) methods, including genomic DNAs and cDNAs. The present nucleic acids are useful as probes for detecting mutations and the methylation patterns of the newly identified genomic loci, and of homologous nucleic acids. Nucleic acids of the present invention are also useful for detecting expression of mRNA from herein identified genes, for
10 measuring expression of those and homologous genes sequences, and for determining suitability of therapeutic treatment. The disclosed nucleic acids and their homologs are useful for inhibition of multiple drug resistance. Cells are disclosed which are useful for identification or modulators of multidrug resistance.

MSAGGDFGNPLRKFKLVFLGEQSVAKTSLITRFRYDSFDNTYQAIIGIDFLSKTMYLEDG	60
MS GGDFGNPLRKFKLVFLGEQSV KTSLITRF YDSFDNTYQA IGIDFLSKTMYLED	
MSTGGDFGNPLRKFKLVFLGEQSVGKTSLITRFMYDSFDNTYQATIGIDFLSKTMYLEDR	60
TIGLRLWDTAGQERLRS LIPRYIRDSAAAVVYDITNVNSFQQTTKWIDDVRTERGSDVI	120
T+ L+LWDTAGQER RSLIP YIRDS AVVYDITNVNSFQQTTKWIDDVRTERGSDVI	
TVRLQLWDTAGQERFRSLIPSYIRDSTVAVVYDITNVNSFQQTTKWIDDVRTERGSDVI	120
ITLVGNRTDLADKRQVSVEEGERKAKGLNVTFIETRAKTGYNVKQLFRRVAAALPGMEST	180
I LVGN+TDLADKRQVS+EEGERKAK LNV FIET AK GYNV KQLFRRVAAALPGMEST	
IMLVGNKTDLADKRQVSIEEGERKAKELNVMFIETSAKAGYNV KQLFRRVAAALPGMEST	180
QDGSREDMSDIKLEKPQEQT VSEGGCSC	208
QD SREDM DIKLEKPQE Q VSEGGCSC	
QDRSREDMIDIKLEKPQE QPVSEGGCSC	208

FIG. 2

AGCTGGCTGGAGCAGCATCGGTCCGGGA_GGTCTCTAGGCTGAGGCGGCGGCCGCTCCTC	409
AGCTGGCTGGAGCAGCATCGGTCCGGGACGGTCTCTAGGCTGAGGCGGCGGCCGCTCCTC	60
TAGTTCACAAATGTCACGGGCGGAGACTTCGGGAATCCGCTGAGGAAATTCAGCTGGT	469
TAGTTCACAAATGTCACGGGCGGAGACTTCGGGAATCCGCTGAGGAAATTCAGCTGGT	120
G TTCCTGGGGGAGCAAAGCGTTGGAAAGACATCTTTGATCACCAGATTCATGTATGACAG	529
G TTCCTGGGGGAGCAAAGCGTTGGAAAGACATCTTTGATCACCAGATTCATGTATGACAG	180
TTTTGACAACACCTATCAGGCAACAATTGGCATTGACTTTTTATCAAAAACCTATGTACTT	589
TTTTGACAACACCTATCAGGCAACAATTGGCATTGACTTTTTATCAAAAACCTATGTACTT	240
GGAGGATCGAACAATCAGGCTTCAGCTGTGGGATACTGCGGGTCAGGAACGTTTCCGTAG	649
GGAGGATCGAACAGTACGATTGCAATTATGGGACACAGCAGGTCAAGAGCGGTTCAGGAG	300
CCTCATTCCCAGTTACATCCGTGATTCTGCTGCAGCTGTAGTAGTTTACGATATCACAAA	709
CTTGATTCTAGCTACATTCGTGACTCCACTGTGGCAGTTGTTGTTTATGATATCACAAA	360
TGTTAACTCATTCCAGCAAACCTACAAAGTGGATTGATGATGTCAGAACAGAAAGAGGAAG	769
TGTTAACTCATTCCAGCAAACCTACAAAGTGGATTGATGATGTCAGAACAGAAAGAGGAAG	420

FIG. 3a

MSTGGDFGNPLRKFKLVFLGEQSVGKTSLITRFMYDSFDNTYQATIGIDFLSKTMYLEDR	60
MSTGGDFGNPLRKFKLVFLGEQSVGKTSLITRFMYDSFDNTYQATIGIDFLSKTMYLEDR	
MSTGGDFGNPLRKFKLVFLGEQSVGKTSLITRFMYDSFDNTYQATIGIDFLSKTMYLEDR	60
TIRLQLWDTAGQERFRSLIPSYIRDSAAAVVVDITNVNSFQOTTKWIDDVRTERGSDVI	120
T+RLQLWDTAGQERFRSLIPSYIRDS AVVVVDITNVNSFQOTTKWIDDVRTERGSDVI	
TVRLQLWDTAGQERFRSLIPSYIRDSTVAVVVVDITNVNSFQOTTKWIDDVRTERGSDVI	120
IMLVGNKTDLADKRQVSIEEGERKAKELNVMFIETSAKAGYNVKQLFRRVAAALPGMEST	180
IMLVGNKTDLADKRQVSIEEGERKAKELNVMFIETSAKAGYNVKQLFRRVAAALPGMEST	
IMLVGNKTDLADKRQVSIEEGERKAKELNVMFIETSAKAGYNVKQLFRRVAAALPGMEST	180
QDRSREDMIDIKLEKPQEQPVSEGGCSC	208
QDRSREDMIDIKLEKPQEQPVSEGGCSC	
QDRSREDMIDIKLEKPQEQPVSEGGCSC	208

FIG. 4



FIG. 5



FIG. 6




FIG. 7




FIG. 8




FIG. 10

SEQUENCE LISTING

<110> Duffy, Hao-Peng Xu

Shan, Ji-dong

Yuan, Li-ming

Dudman, Daniel

Calabro, Anthony

<120> Identification of Differentially Methylated
Multiple Drug Resistance Loci

<130> 52494/2202

<140> filed concurrently herewith

<141> 1999-11-08

<150> US 60/108,994

<151> 1998-11-08

<160> 46

<170> WordPerfect 8.0 for Windows

<210> 1

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic adapter

<400> 1

ctcgtcgtca ggtcagtgtc tcac

24

<210> 2

<211> 12

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic adapter

<400> 2

cggtgaagca ct

12

<210> 3

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic adapter
 <400> 3
 tagagccacg tagctgctgt agtc 24

<210> 4
 <211> 12
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Synthetic adapter
 <400> 4
 cggactacag ca 12

<210> 5
 <211> 24
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Synthetic adapter
 <400> 5
 accgtggact ggataggttc agac 24

<210> 6
 <211> 12
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Synthetic adapter
 <400> 6
 cggctctgaac ct 12

<210> 7
 <211> 573
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> CDS
 <222> 48..573
 <400> 7
 ccgggaggtc tctgggctga ggcggcgaca gctcctctag ttccacc atg tcc gcg 56

150	155	160	
aag cag ctc ttt cga cgt gta gca gca gct ttg ccg g			573
Lys Gln Leu Phe Arg Arg Val Ala Ala Ala Leu Pro			
165	170	175	
<210> 8			
<211> 23			
<212> DNA			
<213> Artificial Sequence			
<220>			
<223> Synthetic primer			
<400> 8			
tcctctagtt ccacatggtc cac			23
<210> 9			
<211> 19			
<212> DNA			
<213> Artificial Sequence			
<220>			
<223> Synthetic primer			
<400> 9			
cacagccgaa gcccgattg			19
<210> 10			
<211> 838			
<212> DNA			
<213> Homo sapiens			
<220>			
<221> CDS			
<222> 48..809			
<400> 10			
ccgggagggtc tctgggctga ggcggcgaca gtcctctag ttccacc atg tcc gcg			56
		Met Ser Ala	

ggc gga gac ttc ggg aat ccg ctg agg aaa ttc aag ctg gtg ttc ctg	104
Gly Gly Asp Phe Gly Asn Pro Leu Arg Lys Phe Lys Leu Val Phe Leu	
5 10 15	
ggg gag caa agc gtt gca aag aca tct ttg atc acc aga ttc agg tat	152
Gly Glu Gln Ser Val Ala Lys Thr Ser Leu Ile Thr Arg Phe Arg Tyr	
20 25 30 35	
gac agt ttt gac aac acc tat cag gca ata att ggc att gac ttt tta	200
Asp Ser Phe Asp Asn Thr Tyr Gln Ala Ile Ile Gly Ile Asp Phe Leu	
40 45 50	
tca aaa act atg tac ttg gag gat gga aca atc ggg ctt cgg ctg tgg	248
Ser Lys Thr Met Tyr Leu Glu Asp Gly Thr Ile Gly Leu Arg Leu Trp	
55 60 65	
gat acg gcg ggt cag gaa cgt ctc cgt agc ctc att ccc agg tac atc	296
Asp Thr Ala Gly Gln Glu Arg Leu Arg Ser Leu Ile Pro Arg Tyr Ile	
70 75 80	
cgt gat tct gct gca gct gta gta gtt tac gat atc aca aat gtt aac	344
Arg Asp Ser Ala Ala Ala Val Val Val Tyr Asp Ile Thr Asn Val Asn	
85 90 95	
tca ttc cag caa act aca aag tgg att gat gat gtc aga aca gaa aga	392
Ser Phe Gln Gln Thr Thr Lys Trp Ile Asp Asp Val Arg Thr Glu Arg	
100 105 110 115	
gga agt gat gtt atc atc acg cta gta gga aat aga aca gat ctt gct	440
Gly Ser Asp Val Ile Ile Thr Leu Val Gly Asn Arg Thr Asp Leu Ala	
120 125 130	
gac aag agg caa gtg tca gtt gag gag gga gag agg aaa gcc aaa ggg	488
Asp Lys Arg Gln Val Ser Val Glu Glu Gly Glu Arg Lys Ala Lys Gly	
135 140 145	
ctg aat gtt acg ttt att gaa act agg gca aaa act gga tac aat gta	536
Leu Asn Val Thr Phe Ile Glu Thr Arg Ala Lys Thr Gly Tyr Asn Val	
150 155 160	

aag cag ctc ttt cga cgt gta gca gca gct ttg ccg gga atg gaa agc 584
Lys Gln Leu Phe Arg Arg Val Ala Ala Ala Leu Pro Gly Met Glu Ser
165 170 175

aca cag gac gga agc aga gaa gac atg agt gac ata aaa ctg gaa aag 632
Thr Gln Asp Gly Ser Arg Glu Asp Met Ser Asp Ile Lys Leu Glu Lys
180 185 190 195

cct cag gag caa aca gtc agc gaa ggg ggt tgt tcc tgc tac tct ccc 680
Pro Gln Glu Gln Thr Val Ser Glu Gly Gly Cys Ser Cys Tyr Ser Pro
200 205 210

atg tca tct tca acc ctt cct cag aag ccc cct tac tct ttc att gac 728
Met Ser Ser Ser Thr Leu Pro Gln Lys Pro Pro Tyr Ser Phe Ile Asp
215 220 225

tgc agt gtg aat att ggc ttg aac ctt ttc cct tca tta ata acg ttt 776
Cys Ser Val Asn Ile Gly Leu Asn Leu Phe Pro Ser Leu Ile Thr Phe
230 235 240

tgc aat tca tca ttg ctg cct gtc tcg tgg aga tgatctatta gcttgacaag 829
Cys Asn Ser Ser Leu Leu Pro Val Ser Trp Arg
245 250 254

cacaaaaaa 838

<210> 11

<211> 762

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> 1..762

<400> 11

atg tcc gcg ggc gga gac ttc ggg aat ccg ctg agg aaa ttc aag ctg 48
Met Ser Ala Gly Gly Asp Phe Gly Asn Pro Leu Arg Lys Phe Lys Leu
1 5 10 15

gtg ttc ctg ggg gag caa agc gtt gca aag aca tct ttg atc acc aga 96
Val Phe Leu Gly Glu Gln Ser Val Ala Lys Thr Ser Leu Ile Thr Arg

20	25	30	
ttc agg tat gac agt ttt gac aac acc tat cag gca ata att ggc att			144
Phe Arg Tyr Asp Ser Phe Asp Asn Thr Tyr Gln Ala Ile Ile Gly Ile			
35	40	45	
gac ttt tta tca aaa act atg tac ttg gag gat gga aca atc ggg ctt			192
Asp Phe Leu Ser Lys Thr Met Tyr Leu Glu Asp Gly Thr Ile Gly Leu			
50	55	60	
cgg ctg tgg gat acg gcg ggt cag gaa cgt ctc cgt agc ctc att ccc			240
Arg Leu Trp Asp Thr Ala Gly Gln Glu Arg Leu Arg Ser Leu Ile Pro			
65	70	75	80
agg tac atc cgt gat tct gct gca gct gta gta gtt tac gat atc aca			288
Arg Tyr Ile Arg Asp Ser Ala Ala Ala Val Val Val Tyr Asp Ile Thr			
85	90	95	
aat gtt aac tca ttc cag caa act aca aag tgg att gat gat gtc aga			336
Asn Val Asn Ser Phe Gln Gln Thr Thr Lys Trp Ile Asp Asp Val Arg			
100	105	110	
aca gaa aga gga agt gat gtt atc atc acg cta gta gga aat aga aca			384
Thr Glu Arg Gly Ser Asp Val Ile Ile Thr Leu Val Gly Asn Arg Thr			
115	120	125	
gat ctt gct gac aag agg caa gtg tca gtt gag gag gga gag agg aaa			432
Asp Leu Ala Asp Lys Arg Gln Val Ser Val Glu Glu Gly Glu Arg Lys			
130	135	140	
gcc aaa ggg ctg aat gtt acg ttt att gaa act agg gca aaa act gga			480
Ala Lys Gly Leu Asn Val Thr Phe Ile Glu Thr Arg Ala Lys Thr Gly			
145	150	155	160
tac aat gta aag cag ctc ttt cga cgt gta gca gca gct ttg ccg gga			528
Tyr Asn Val Lys Gln Leu Phe Arg Arg Val Ala Ala Ala Leu Pro Gly			
165	170	175	
atg gaa agc aca cag gac gga agc aga gaa gac atg agt gac ata aaa			576
Met Glu Ser Thr Gln Asp Gly Ser Arg Glu Asp Met Ser Asp Ile Lys			

Asn Val Asn Ser Phe Gln Gln Thr Thr Lys Trp Ile Asp Asp Val Arg
100 105 110

Thr Glu Arg Gly Ser Asp Val Ile Ile Thr Leu Val Gly Asn Arg Thr
115 120 125

Asp Leu Ala Asp Lys Arg Gln Val Ser Val Glu Glu Gly Glu Arg Lys
130 135 140

Ala Lys Gly Leu Asn Val Thr Phe Ile Glu Thr Arg Ala Lys Thr Gly
145 150 155 160

Tyr Asn Val Lys Gln Leu Phe Arg Arg Val Ala Ala Ala Leu Pro Gly
165 170 175

Met Glu Ser Thr Gln Asp Gly Ser Arg Glu Asp Met Ser Asp Ile Lys
180 185 190

Leu Glu Lys Pro Gln Glu Gln Thr Val Ser Glu Gly Gly Cys Ser Cys
195 200 205

Tyr Ser Pro Met Ser Ser Ser Thr Leu Pro Gln Lys Pro Pro Tyr Ser
210 215 220

Phe Ile Asp Cys Ser Val Asn Ile Gly Leu Asn Leu Phe Pro Ser Leu
225 230 235 240

Ile Thr Phe Cys Asn Ser Ser Leu Leu Pro Val Ser Trp Arg
245 250 254

<210> 13
<211> 18
<212> DNA
<213> Homo sapiens
<400> 13
gga aca atc ggg ctt cgg
Gly Thr Ile Gly Leu Arg
1 5

18

<210> 14

<211> 21
 <212> DNA
 <213> Homo sapiens
 <400> 14
 ctc cgt agc ctc att ccc agg 21
 Leu Arg Ser Leu Ile Pro Arg
 1 5

<210> 15
 <211> 39
 <212> DNA
 <213> Homo sapiens
 <400> 15
 ggg ctg aat gtt acg ttt att gaa act agg gca aaa act 39
 Gly Leu Asn Val Thr Phe Ile Glu Thr Arg Ala Lys Thr
 1 5 10

<210> 16
 <211> 21
 <212> DNA
 <213> Homo sapiens
 <400> 16
 gga agc aga gaa gac atg agt 21
 Gly Ser Arg Glu Asp Met Ser
 1 5

<210> 17
 <211> 15
 <212> DNA
 <213> Homo sapiens
 <400> 17
 gag caa aca gtc agc 15
 Glu Gln Thr Val Ser
 1 5

<210> 18
 <211> 138
 <212> DNA
 <213> Homo sapiens
 <400> 18

tac tct ccc atg tca tct tca acc ctt cct cag aag ccc cct tac tct 48
Tyr Ser Pro Met Ser Ser Ser Thr Leu Pro Gln Lys Pro Pro Tyr Ser
1 5 10 15

ttc att gac tgc agt gtg aat att ggc ttg aac ctt ttc cct tca tta 96
Phe Ile Asp Cys Ser Val Asn Ile Gly Leu Asn Leu Phe Pro Ser Leu
20 25 30

ata acg ttt tgc aat tca tca ttg ctg cct gtc tcg tgg aga 138
Ile Thr Phe Cys Asn Ser Ser Leu Leu Pro Val Ser Trp Arg
35 40 45

<210> 19

<211> 6

<212> PRT

<213> Homo sapiens

<400> 19

Gly Thr Ile Gly Leu Arg

1 5

<210> 20

<211> 7

<212> PRT

<213> Homo sapiens

<400> 20

Leu Arg Ser Leu Ile Pro Arg

1 5

<210> 21

<211> 13

<212> PRT

<213> Homo sapiens

<400> 21

Gly Leu Asn Val Thr Phe Ile Glu Thr Arg Ala Lys Thr

1 5 10

<210> 22

<211> 7

<212> PRT

<213> Homo sapiens

<400> 22

Gly Ser Arg Glu Asp Met Ser

1

5

<210> 23

<211> 5

<212> PRT

<213> Homo sapiens

<400> 23

Glu Gln Thr Val Ser

1

5

<210> 24

<211> 46

<212> PRT

<213> Homo sapiens

<400> 24

Tyr Ser Pro Met Ser Ser Ser Thr Leu Pro Gln Lys Pro Pro Tyr Ser

1

5

10

15

Phe Ile Asp Cys Ser Val Asn Ile Gly Leu Asn Leu Phe Pro Ser Leu

20

25

30

Ile Thr Phe Cys Asn Ser Ser Leu Leu Pro Val Ser Trp Arg

35

40

45

<210> 25

<211> 1460

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> 420..1043

<220>

<223> cDNA (composite of multiple cDNA clones)

<400> 25

gaattccggg cagctgtgga agctcaggcg ctgcgcgtga gaggtcccag atacgtctgc 60

ggttccggct ccgccaccct cagcttctct tccccagggtc tgggagccga gtgcggaagg 120

```

agggaaacggc cctagctttg ggaagccaga ggacaccctt ggctcctgcc gacaccgccc 180

tccttccctt cccagccgcg ggctcgtctc ggtgctaggc tactctgccg ggaggcggcg 240

gcggctgcca gtctgtggag agtcctgctg ccctccagcc gggctcctcc accgggcctt 300

gcagggggcg agagagctcg gtgcccggcc ttccgctcgc ctttttcgtc agctggctgg 360

agcagcatcg gtccgggagg tctctaggct gaggcggcgg ccgctcctct agttccaca 419

atg tcc acg ggc gga gac ttc ggg aat ccg ctg agg aaa ttc aag ctg 467
Met Ser Thr Gly Gly Asp Phe Gly Asn Pro Leu Arg Lys Phe Lys Leu
  1           5           10          15

gtg ttc ctg ggg gag caa agc gtt gga aag aca tct ttg atc acc aga 515
Val Phe Leu Gly Glu Gln Ser Val Gly Lys Thr Ser Leu Ile Thr Arg
      20           25           30

ttc atg tat gac agt ttt gac aac acc tat cag gca aca att ggc att 563
Phe Met Tyr Asp Ser Phe Asp Asn Thr Tyr Gln Ala Thr Ile Gly Ile
      35           40           45

gac ttt tta tca aaa act atg tac ttg gag gat cga aca atc agg ctt 611
Asp Phe Leu Ser Lys Thr Met Tyr Leu Glu Asp Arg Thr Ile Arg Leu
      50           55           60

cag ctg tgg gat act gcg ggt cag gaa cgt ttc cgt agc ctc att ccc 659
Gln Leu Trp Asp Thr Ala Gly Gln Glu Arg Phe Arg Ser Leu Ile Pro
      65           70           75           80

agt tac atc cgt gat tct gct gca gct gta gta gtt tac gat atc aca 707
Ser Tyr Ile Arg Asp Ser Ala Ala Ala Val Val Val Tyr Asp Ile Thr
      85           90           95

aat gtt aac tca ttc cag caa act aca aag tgg att gat gat gtc aga 755
Asn Val Asn Ser Phe Gln Gln Thr Thr Lys Trp Ile Asp Asp Val Arg
      100          105          110

```

aca gaa aga gga agt gat gtt atc atc atg cta gta gga aat aaa aca 803
 Thr Glu Arg Gly Ser Asp Val Ile Ile Met Leu Val Gly Asn Lys Thr
 115 120 125

gat ctt gct gac aag agg caa gtg tca att gag gag gga gag agg aaa 851
 Asp Leu Ala Asp Lys Arg Gln Val Ser Ile Glu Glu Gly Glu Arg Lys
 130 135 140

gcc aaa gag ctg aat gtt atg ttt att gaa act agt gca aaa gct gga 899
 Ala Lys Glu Leu Asn Val Met Phe Ile Glu Thr Ser Ala Lys Ala Gly
 145 150 155 160

tac aat gta aag cag ctc ttt cga cgt gta gca gca gct ttg ccg gga 947
 Tyr Asn Val Lys Gln Leu Phe Arg Arg Val Ala Ala Ala Leu Pro Gly
 165 170 175

atg gaa agc aca cag gac aga agc aga gaa gat atg att gac ata aaa 995
 Met Glu Ser Thr Gln Asp Arg Ser Arg Glu Asp Met Ile Asp Ile Lys
 180 185 190

ctg gaa aag cct cag gag caa cca gtc agt gaa gga ggc tgt tcc tgc 1043
 Leu Glu Lys Pro Gln Glu Gln Pro Val Ser Glu Gly Gly Cys Ser Cys
 195 200 205

taatctccca tgtcatcttc aaccttcttc agaagctcac tgctttggcc cccttactct 1103

ttcattgact gcagtgtgaa tattggcttg aaccttttcc cttcagtaat aacgtattgc 1163

aattcatcat tgctgcctgt ctggtggaga tgatctatta gcttcacaag cacaacaaaa 1223

gtcagtgtct tcattattta tattttacaa aaagccaaaa tatttcagca tattccagtg 1283

ataactttaa aaattagata cattttctta acattttttt cttttttaat gttatgataa 1243

tgtacttcaa aatgatggaa atctcaacag tatgagtatg gcttggttaa cgagcggtat 1403

gttcacagcc tactttatct ctcttgctt ttctcacctc tcacttacct ggaattc 1460

<210> 26
 <211> 624

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> 1..624

<220>

<223> coding region of cDNA

<400> 26

atg	tcc	acg	ggc	gga	gac	ttc	ggg	aat	ccg	ctg	agg	aaa	ttc	aag	ctg	48
Met	Ser	Thr	Gly	Gly	Asp	Phe	Gly	Asn	Pro	Leu	Arg	Lys	Phe	Lys	Leu	
1				5					10					15		

gtg	ttc	ctg	ggg	gag	caa	agc	ggt	gga	aag	aca	tct	ttg	atc	acc	aga	96
Val	Phe	Leu	Gly	Glu	Gln	Ser	Val	Gly	Lys	Thr	Ser	Leu	Ile	Thr	Arg	
			20					25					30			

ttc	atg	tat	gac	agt	ttt	gac	aac	acc	tat	cag	gca	aca	att	ggc	att	144
Phe	Met	Tyr	Asp	Ser	Phe	Asp	Asn	Thr	Tyr	Gln	Ala	Thr	Ile	Gly	Ile	
		35					40					45				

gac	ttt	tta	tca	aaa	act	atg	tac	ttg	gag	gat	cga	aca	atc	agg	ctt	192
Asp	Phe	Leu	Ser	Lys	Thr	Met	Tyr	Leu	Glu	Asp	Arg	Thr	Ile	Arg	Leu	
	50					55					60					

cag	ctg	tgg	gat	act	gcg	ggt	cag	gaa	cgt	ttc	cgt	agc	ctc	att	ccc	240
Gln	Leu	Trp	Asp	Thr	Ala	Gly	Gln	Glu	Arg	Phe	Arg	Ser	Leu	Ile	Pro	
65					70				75					80		

agt	tac	atc	cgt	gat	tct	gct	gca	gct	gta	gta	gtt	tac	gat	atc	aca	288
Ser	Tyr	Ile	Arg	Asp	Ser	Ala	Ala	Ala	Val	Val	Val	Tyr	Asp	Ile	Thr	
					85				90					95		

aat	gtt	aac	tca	ttc	cag	caa	act	aca	aag	tgg	att	gat	gat	gtc	aga	336
Asn	Val	Asn	Ser	Phe	Gln	Gln	Thr	Thr	Lys	Trp	Ile	Asp	Asp	Val	Arg	
				100				105						110		

aca	gaa	aga	gga	agt	gat	gtt	atc	atc	atg	cta	gta	gga	aat	aaa	aca	384
Thr	Glu	Arg	Gly	Ser	Asp	Val	Ile	Ile	Met	Leu	Val	Gly	Asn	Lys	Thr	
				115				120						125		

gat ctt gct gac aag agg caa gtg tca att gag gag gga gag agg aaa 432
 Asp Leu Ala Asp Lys Arg Gln Val Ser Ile Glu Glu Gly Glu Arg Lys
 130 135 140

gcc aaa gag ctg aat gtt atg ttt att gaa act agt gca aaa gct gga 480
 Ala Lys Glu Leu Asn Val Met Phe Ile Glu Thr Ser Ala Lys Ala Gly
 145 150 155 160

tac aat gta aag cag ctc ttt cga cgt gta gca gca gct ttg ccg gga 528
 Tyr Asn Val Lys Gln Leu Phe Arg Arg Val Ala Ala Ala Leu Pro Gly
 165 170 175

atg gaa agc aca cag gac aga agc aga gaa gat atg att gac ata aaa 576
 Met Glu Ser Thr Gln Asp Arg Ser Arg Glu Asp Met Ile Asp Ile Lys
 180 185 190

ctg gaa aag cct cag gag caa cca gtc agt gaa gga ggc tgt tcc tgc 624
 Leu Glu Lys Pro Gln Glu Gln Pro Val Ser Glu Gly Gly Cys Ser Cys
 195 200 205

<210> 27

<211> 208

<212> PRT

<213> Homo sapiens

<400> 27

Met Ser Thr Gly Gly Asp Phe Gly Asn Pro Leu Arg Lys Phe Lys Leu
 1 5 10 15

Val Phe Leu Gly Glu Gln Ser Val Gly Lys Thr Ser Leu Ile Thr Arg
 20 25 30

Phe Met Tyr Asp Ser Phe Asp Asn Thr Tyr Gln Ala Thr Ile Gly Ile
 35 40 45

Asp Phe Leu Ser Lys Thr Met Tyr Leu Glu Asp Arg Thr Ile Arg Leu
 50 55 60

Gln Leu Trp Asp Thr Ala Gly Gln Glu Arg Phe Arg Ser Leu Ile Pro
 65 70 75 80

Ser Tyr Ile Arg Asp Ser Ala Ala Ala Val Val Val Tyr Asp Ile Thr
85 90 95

Asn Val Asn Ser Phe Gln Gln Thr Thr Lys Trp Ile Asp Asp Val Arg
100 105 110

Thr Glu Arg Gly Ser Asp Val Ile Ile Met Leu Val Gly Asn Lys Thr
115 120 125

Asp Leu Ala Asp Lys Arg Gln Val Ser Ile Glu Glu Gly Glu Arg Lys
130 135 140

Ala Lys Glu Leu Asn Val Met Phe Ile Glu Thr Ser Ala Lys Ala Gly
145 150 155 160

Tyr Asn Val Lys Gln Leu Phe Arg Arg Val Ala Ala Ala Leu Pro Gly
165 170 175

Met Glu Ser Thr Gln Asp Arg Ser Arg Glu Asp Met Ile Asp Ile Lys
180 185 190

Leu Glu Lys Pro Gln Glu Gln Pro Val Ser Glu Gly Gly Cys Ser Cys
195 200 205

<210> 28
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic primer
<400> 28
tcctctagtt ccaccatgtc cgc

23

<210> 29
<211> 17
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic primer
<400> 29

gtaaaacgac ggccagt 17

<210> 30

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic primer

<400> 30

agcggataac aatttcacac agga 24

<210> 31

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic primer

<400> 31

tcctctagtt ccacaatgtc c 21

<210> 32

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic primer

<400> 32

gcaatcgtac tgttcgatc 19

<210> 33

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic primer

<400> 33

cggagtcaac ggatttggtc gtat 24

<210> 34

<211> 24

<212> DNA
 <213> Artificial Sequence
 <220>
 <223> Synthetic primer
 <400> 34
 agccttctcc atggtggtga agac 24

<210> 35
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Synthetic primer
 <400> 35
 gctgaggaaa ttcaagctgg 20

<210> 36
 <211> 22
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Synthetic primer
 <400> 36
 caacaactgc cacagtggag tc 22

<210> 37
 <211> 22
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Synthetic primer
 <400> 37
 ctactacagc tgcagcagaa tc 22

<210> 38
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Synthetic primer

<400> 38	
acgacatgga gaagatctgg c	21
<210> 39	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic primer	
<400> 39	
ttctcgatgc tcgacgggct acc	23
<210> 40	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic primer	
<400> 40	
gatggaacaa tcgggcttcg	20
<210> 41	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic primer	
<400> 41	
aaacagtcag cgaagggggt	20
<210> 42	
<211> 22	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic primer	
<400> 42	
gtagcaggaa caacccccctt cg	22
<210> 43	

<211> 21	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic primer	
<400> 43	
gatcgaacaa tcaggcttca g	21
<210> 44	
<211> 21	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic primer	
<400> 44	
aagggggcca aagcagtgag c	21
<210> 45	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic primer	
<400> 45	
ggatcgaaca gtacgattgc	20
<210> 46	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic primer	
<400> 46	
gctgctgcta cacgtcgaaa gag	23